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C-to-U RNA editing has been implicated as possibly either adaptive or maladaptive mechanism 
in temporal lobe epilepsy (TLE), the most common form of focal epilepsy with a persistently high 
rate of pharmacoresistance, despite an abundance of available antiepileptic drugs. C-to-U RNA-
edited glycine receptors (edGlyR) might present a novel drug target for treatment of 
pharmacoresistant TLE. Previous studies have shown elevated expression of edGlyR in resected 
hippocampi of TLE patients, which correlated with the degree of hippocampal sclerosis. C-to-U 
RNA editing of GlyR mRNA leads to a gain of function, resulting in an increased affinity for glycine. 
edGlyR act predominantly in presynaptic compartments, where they facilitate neurotransmitter 
release and, depending on neuron type afflicted with edGlyR expression, induce network hyper- 
or hypoexcitability. C-to-U RNA editing of GlyR mRNA could therefore contribute to seizure 
generation or represent an adaptive mechanism to decrease hyperexcitability. 
The aim of this thesis was to identify specific edGlyR antagonists and investigate their effect on 
epileptic activity in human brain ex vivo, as well as identify the neuronal cell type expressing 
edGlyR using a novel RNAediting sensor tool in human brain slice cultures. Using high-throughput 
screening methods and database research, I was unable to identify a specific edGlyR antagonist. 
However, one of the molecules tested as a potential edGlyR antagonist, dimethylethanolamine 
(DMEA), has been tested as treatment option for different neurological disorders, although 
detailed functional mechanisms are still unknown. Here, I showed that DMEA decreased 
spontaneous activity in primary neuronal cultures and displayed an antiepileptic effect in patient-
derived brain tissue ex vivo. In addition, I established stable viral mediated expression of the RNA-
editing sensor tool in human brain slice cultures and showed neuron-specific expression. 
I propose that application of DMEA as well as identification of RNA-editing on single cell level in 
human brain tissue present valuable tools for the development of novel therapeutic options in 




C-zu-U RNA-Editierung wurde sowohl als adaptiver als auch maladaptiver Prozess bei 
Temporallappenepilepsie (TLE) beschrieben. TLE ist die häufigste Form der fokalen Epilepsie, 
mit einem hohen Anteil an pharmakoresistenten Verläufen, trotz einer Vielzahl an verfügbaren 
antiepileptischen Substanzen. Einen neuen potentiell antiepileptischen Mechanismus stellen 
RNA-editierte Glyzinrezeptoren (edGlyR) dar. Hippocampi von Patienten mit pharmakoresistenter 
TLE zeigen eine Überexpression von edGlyR mRNA, welche mit der Schwere der Hippocampus-
Sklerose korreliert. C-zu-U RNA-Editierung der GlyR mRNA führt zu einem Funktionsgewinn und 
zu einer erhöhten Affinität für Glyzin. edGlyR wirken überwiegend präsynaptisch, wo sie die 
Freisetzung von Neurotransmittern erhöhen und bedingt durch die Lokalisation auf inhibitorischen 
oder exzitatorischen Neuronen zu einer verstärkten oder verminderten neuronalen Erregbarkeit 
führen. Die C-zu-U RNA-Editierung der GlyR mRNA könnte daher zur Anfallsgenerierung 
beitragen oder einen adaptiven Mechanismus zur Verringerung der Übererregbarkeit darstellen. 
Ziel dieser Arbeit war es, spezifische edGlyR-Antagonisten zu identifizieren und ihren Einfluss 
auf epileptische Aktivität im humanen Gehirn ex vivo zu untersuchen sowie mit Hilfe eines RNA-
Editierungssensors das Expressionsmuster von edGlyR auf Einzelzellebene in humanen 
Hirnschnittkulturen zu identifizieren. Weder mittels high-throughput Screening noch 
strukturbasierter Datenbankanalyse konnten jedoch in dieser Arbeit spezifische Antagonisten für 
edGlyR identifiziert werden. Eine der getesteten potentiellen edGlyR Antagonisten, 
Dimethylethanolamin (DMEA), wurde bereits in diversen präklinischen und klinischen Studien als 
Therapie für neurologische Erkrankungen getestet, jedoch ohne detailliertes Wissen über den 
Wirkmechanismus. In dieser Arbeit konnte ich zeigen, dass DMEA die spontane Aktivität von 
primären neuronalen Kulturen reduziert sowie antiepileptische Effekte in reseziertem humanem 
Hirngewebe von TLE Patienten aufweist. Zudem konnte ich eine stabile viral-vermittelte 
Expression des RNA-Editierungssensors spezifisch in Neuronen von humanen 
Hirnschnittkulturen zeigen. 
Die Anwendung von DMEA als antiepileptische Substanz sowie die Identifizierung von RNA-
Editierung auf Einzelzellenebene stellen essentielle Werkzeuge für die Entwicklung neuartiger 




Epilepsy is a life-altering neurological disorder affecting up to 1% of the world population1,2. 
Epilepsy types can be classified as generalized or focal by the type of seizure onset; generalized 
seizures show an onset in networks of both hemispheres whereas focal seizures originate from 
one hemisphere3. 30-40% of patients diagnosed with focal epilepsy develop pharmacoresistance 
and do not respond to currently available antiepileptic drugs (AEDs) despite treatments with 
multiple AEDs at high dosages4. 
Ketogenic diet and deep brain stimulation have been investigated in detail as alternative therapies 
to reduce seizure burden in such patients5–7. Ketogenic diet is mostly effective in children, and is 
also able to reduce seizure frequency in adults, but this approach is not standard of care for adult 
epilepsy patients8,9. Deep brain stimulation is still part of ongoing investigations, as it has been 
shown to be promising in terms of seizure reduction in patients with pharmacoresistant epilepsy10. 
Nevertheless, selection of targeted brain regions and prospective trials are still lacking. Finally, 
surgical resection of the epileptic focus is a successful treatment option11,12. 60-70% of resected 
patients have a positive outcome with seizure freedom or substantial reduction of seizure burden 
(International League Against Epilepsy Outcome Scale 1-2), while no effective therapy exists for 
the remaining patients13. Given these numbers, it is of vital importance to investigate new 
treatment options against focal pharmacoresistant epilepsy. 
In temporal lobe epilepsy (TLE), the most common form of focal epilepsy in humans14, RNA-
editing has been suggested as a key mechanism during epileptogenesis. RNA editing is a 
posttranscriptional modification that results in sequence changes of RNA transcripts and thus 
increases the transcriptome size15,16. Upregulation of RNA editing in TLE has been described for 
several targets17–20. In a mouse model of TLE, RNA editing of epilepsy-related genes was not only 
upregulated but also positively correlated with seizure frequency17, indicating the functional 
relevance of this mechanism. 
Glycine receptor (GlyR) RNA was previously identified as a target of RNA editing in TLE18,21. 
Upregulation of C-to-U RNA editing of GlyR was demonstrated in resected hippocampal tissue of 
TLE patients, and the degree of editing positively correlated with the degree of hippocampal 
sclerosis18. On a functional level, C-to-U edited GlyR (edGlyR) display increased affinity for 
glycine18,21 and an altered presynaptic function. Similar to presynaptically expressed unedited 
GlyR or GABAR, edGlyRs are considered to contribute to changes of network excitability in 
epilepsy due to high chloride concentration in the presynaptic compartment22–25. Here, edGlyR 
facilitate neurotransmitter release resulting in increased neuronal gain and, depending on the 
neuron type afflicted with edGlyR function, network hyper- or hypoexcitability19,26. As 
demonstrated in neuron type-specific mouse models19,26, edGlyR function in glutamatergic 
neurons leads to increased network excitability and cognitive dysfunctions whereas their function 
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in parvalbumin-positive GABAergic interneurons decreases network excitability and facilitates 
persistence of contextual fear memory. Thus, depending on the neuronal cell type involved, RNA 
editing of GlyR could increase or decrease seizure threshold in TLE. To test this hypothesis, 
specific tools that analyze edGlyR expression patterns are required. 
Unedited GlyRs have been investigated as possible antiepileptic targets in the past. Kirchner et 
al. (2003) reported bimodal effects of glycine on epileptic activity in vitro: while high concentration 
of glycine increased frequency of epileptic activity, low concentrations delayed its onset27. The 
opposite was reported by Chen et al. (2014), who observed that 100 µM glycine attenuate 
epileptic activity by activation of somatodendritic GlyR and enhanced tonic inhibition, but 10 µM 
enhance epileptic activity presumably by activation of presynaptic GlyR expressed at 
glutamatergic terminals28. In a different approach, increase of endogenous glycine concentration 
by pharmacological block or genetic ablation of the sodium/chloride/glycine symporter GlyT1 
resulted in a decrease of acute and chronic seizure activity in rodent models of TLE29. Irrespective 
of the reported effects, clinical application of glycine for antiepileptic purposes is limited, as it 
would also affect GlyR mediated inhibition in the spinal cord and brain stem. Even more 
importantly, regulation of endogenous glycine is not expected to affect spontaneous edGlyR 
activity19. Thus, in patients with TLE, rather specific edGlyR modulation might be effective. 
The aim of my thesis was to identify and characterize specific edGlyR antagonists in cell culture 
experiments and investigate their effect regarding seizure-like activity in human epileptic tissue 
ex vivo. In addition, I aimed to establish a RNA-editing sensor tool in human brain slice culture 




4. Material and Methods 
HEK 293T cell culture and transfection 
Human embryonal kidney-derived cells (HEK293T) were maintained in DMEM (Invitrogen, 
Carlsbad CA, USA) supplemented with 10% fetal bovine serum (Biochrom) and penicillin 
(100 U/ml) / streptomycin (100 mg/ml) (Invitrogen, Carlsbad CA, USA) and cultured at 37°C, 
5% CO2 in a humidified incubator. 
For high-throughput screening, cells were transfected with a total of 4 µg cDNA per 6 cm dish 
using 25 µl PolyFect transfection reagent (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. HEK cells were co-transfected with GlyR subunits and chloride 
indicator YFPI152L (ratio 1:1). 24 h after transfection 2.5x 104 cells were plated into each well of 
a transparent 96-well plate (TPP) and fluorescence imaging experiments were carried out on the 
following day30. 
For patch clamp experiments, HEK cells were transfected with a total of 1 µg GlyR α2 or α3 coding 
plasmid DNA using FuGENE® HD transfection reagent (catalog no. 04 709 705 001, Roche 
Applied Science) according to the manufacturer's instructions. GlyR α2 constructs were 
cotransfected with 0.1 µg of an N1-EGFP-containing plasmid. On the following day, HEK293T 
cells were seeded onto polyornithine-coated glass coverslips (diameter 13 mm, Hecht Assistant, 
Germany; 0.1% poly-dl-ornithine hydrobromide, catalog no. P8638-100MG, Sigma). Before 
electrophysiological recordings cells were allowed to adhere for at least 1 h. 
Primary rat hippocampal neuronal cell culture 
Primary neuronal cell cultures were prepared from E18 Wistar rat embryos as previously 
described19. Permit was given by the Animal Care Committee of the Technical University 
Braunschweig (Zentrale Einrichtung für Tierhaltung der TU Braunschweig, §4 10.15.M TSB TU 
BS). Cultures were maintained in Neurobasal medium supplemented with B27 and 1% FCS and 
subjected to whole cell patch clamp analysis at DIV13-16 to ensure that the cultures were mature 
enough to display synaptic activity31. 
High-throughput screening HEK 293T cells 
Approximately 1 h prior to experiments, culture medium was replaced by 50 μl control solution, 
containing (in mM): NaCl (140), KCl (5), CaCl2 (2), MgCl2 (1), HEPES (10), and glucose (10) 
(pH 7.4, NaOH). The 96-well plates were placed onto the 3D printed motorized stage of an in 
house-built imaging system including an autosampler for liquid handling (HTS PAL, CTC 
Analytics, Switzerland), an inverted digital fluorescence microscope (Thorlabs, USA) with 
10x objective (Olympus, Japan), CCD camera (Point Grey Research Inc., USA) and LED light 
source (LUMITRONIX, Germany). Cells were imaged in 50 µl control solution (control image) and 
again 8 sec after injection of 100 µl test solution (test image). Test solution was automatically 
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applied and contained (in mM): NaI (140), KCl (5), CaCl2 (2), MgCl2 (1), HEPES (10), glucose 
(10) (pH 7.4, NaOH). To determine EC50 of all tested glycine subunits in our experimental setup 
the applied test solution contained increasing concentrations of glycine. The fluorescence signal 
of identified cells was measured in control and test images as the mean of all pixel values within 
the area of a cell. ‘% fluorescence quench’ in chloride imaging experiments was defined as 
%fluorescence quench=(Finit-Ffinal)* 100 Finit⁄  
where Finit and Ffinal are the initial (of control image) and final (of test image) values of fluorescence, 
respectively30,32. 
For high-throughput screening experiments, control solution was supplemented with compounds 
of the NIH Clinical Collection small molecule compound libraries (I & II) and test solution was 
supplemented with identified EC50 for the each GlyR subunit from the prior experiment. All drugs 
were diluted from stocks at the day of the experiment and added in a final concentration of 10 
µM. All experiments were conducted at room temperature. 
Whole cell patch clamp recordings 
For whole cell patch clamp recordings in HEK cells and cultured neurons, pipettes were made 
from borosilicate glass (Science Products, Hofheim, Germany), with a resistances of 4-7 MΩ and 
filled with the intracellular solution containing (in mM): CsCl (130), NaCl (5), CaCl2 (0.5), 
MgCl2 (1), EGTA (5) and HEPES (30), pH 7.2 (CsOH). Extracellular solution was supplied by 
gravity using a perfusion pencil (Automate Scientific, Inc. Berkeley, USA) for fast solution 
exchange. HEK cells were perfused with extracellular solution E1 containing (in mM): NaCl (140), 
KCl (5), MgCl2 (1), CaCl2 (2), HEPES-NaOH (10) and glucose (10), pH 7.4 (NaOH). For neuronal 
experiments, we applied carbongenated aCSF containing (in mM): NaCl (125), KCl (2), MgCl2 (1), 
CaCl2 (2), NaHCO3 (25), NaH2PO4 (1.25) and glucose (10), pH 7.4. Signals were recoded using 
a EPC-7 amplifier (List-Medical, Darmstadt, Germany), ITC-18 interface and Patchmaster 
software (both HEKA, Lamprecht, Germany).  
All cells were first clamped at a holding potential of -50 mV. Series resistances (Rs) were 
monitored by 5 mV voltage pulses (50 ms) applied every 5 s and varied between 20 MΩ and 
40 MΩ for HEK293T cells and 10 MΩ and 30 MΩ for cultured hippocampal neurons. Data was 
acquired with a sampling rate of 20 kHz and filtered at 2.8 kHz. All experiments were carried out 
at 24°C. 
HEK cells were visualized using a Zeiss Axioscope 10 (Carl Zeiss, Jena, Germany) equipped with 
a 40x objective, a custom made eGFP filter set (Chroma Technology GmbH), an Uniblitz 
electronic shutter and a Spot Pursuit 2 M pixel monochrome CCD camera. HEK cells were 
recorded in voltage clamp mode for recording of current responses to glycine application (1 mM 
for unedited GlyR, 100 µM glycine for the edGlyR). Potential antagonists (DMEA, sarcosine and 
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methylamine hydrochloride, all from Sigma-Aldrich Sigma-Aldrich, Munich, Germany) were added 
to E1 and co-applied with glycine to record dose-response curves (0.1 mM to 50 mM of the tested 
molecule). The following sequence was applied to test effects on glycine mediated currents: 5 s 
glycine, 5 s glycine + test molecule, 5 s glycine, following wash out for 45 s with E1, before 
additional applications. In this way, the tested molecules were applied during steady state phase 
of glycine evoked currents. DMEA increases pH of extracellular solutions, therefore recordings 
with and without adjusting pH using 100% acetic acid (final pH 7.4) were performed. 
The effect of DMEA on spontaneous neuronal activity was tested in current clamp mode, and 
membrane potentials were held around -50 mV by steady current injection, which never exceeded 
150 pA. DMEA was applied for 60 s to investigate effects on spontaneous activity, following 
3-5  min wash-out with aCSF before stepwise increase of DMEA concentration (0.5, 2, 5 or 
10 mM). Action potential (AP) threshold was investigated by short current injections of 10 pA 
steps with or without application of DMEA. AP threshold was determined as the mean of the 
minimum membrane potential necessary for AP generation and membrane potential of the 
previous step current31. 
Human tissue transport and preparation for acute recordings 
Human hippocampal tissue was collected from 12 TLE patients, who all gave written consent prior 
to the procedure. Experiments were approved by the Ethics Committee of Charité-
Universitätsmedizin Berlin on 01.11.2014 (EA2/111/14) and performed in agreement with the 
Declaration of Helsinki. For details on tissue transport and preparation, see Kraus et al., 201931. 
Shortly, tissue was transported from the operation room in chilled carbogenated transport solution 
and cut to 400 µm slices using a vibratome (Leica VT1200S, Wetzlar, Germany) for minimal tissue 
damage. Slices were stored in an interface chamber and continuously perfused (1.6 ml/min) with 
carbogenated aCSF (32°C) until recording. 
For electrophysiological recording, slices were transferred to submerged-type recording chamber 
with high flow rates (10 ml/min) to assure optimal oxygenation and drug application. Epileptic 
activity was induced by elevation of KCl concentration to 8 mM and application of K-channel 
blocker 4-aminopyridine (4-AP, 100 µM, Sigma, Munich, Germany). Epileptiform activity was 
recorded for at least 20 min before 20 min of drug application, following 20 min wash out. For 
control of hyperosmotic effects, the recording sequence stated above was modified and consisted 
of the following steps: 1) baseline with stable epileptiform activity (≥ 10 min); 2) 10 mM sucrose 
(≥ 20 min), 3) wash-out sucrose (≥ 10 min), 4) 10 mM DMEA (≥ 20 min), 5) wash-out DMEA 
(≥ 20 min). Applied substances were the following: DMEA (Sigma-Aldrich, Munich, Germany), 




Human organotypic brain slice cultures and AAV transduction 
Tissue preparation was performed at the Cortex & Epilepsie group of Richard Miles at the Inserm, 
Paris. Human cortical slice cultures were prepared from surgically excised tissue blocks of human 
temporal lobe and peri-tumoral or dysplasic cortex. All patients gave their written, informed 
consent and procedures were approved by the Comité de protection des personnes, Ile de 
France 1 (C16-16, 20152482) and the Consultatif National d’Ethique.  
For details on transport and tissue preparation, see Le Duigou et al, 201833. Shortly, tissue was 
transported and sliced to 300 µm slices in chilled, carbogenated sucrose aCSF. After cutting, 
slices were washed in carbogenated Hanks balanced salt solution (HBSS, Invitrogen, Carlsbad 
CA, USA) with 20 mM HEPES (Invitrogen, Carlsbad CA, USA) for 15 min at room temperature. 
Preparation was performed under sterile conditions to prevent contaminations. Slices were finally 
placed on cell culture insert (30 mm, Merck-Millipore, Darmstadt, Germany) in a 6-well plate with 
1 ml of organotypic slice culture medium (OSCM) with 20 mM HEPES. OSCM was prepared 
according to previous publication34 and contained various added substances as well as Antibiotic-
Antimycotic mix (Invitrogen, Carlsbad CA, USA). OSCM was exchanged after 1 h to OSCM 
without HEPES and exchanged daily. Antibiotics were omitted from OSCM after one week. Slices 
were cultured in humidified incubator with 5% CO2 at 37°C. 
Adeno-associated virus (AAV) transduction of RNAed sensor (fusion protein with mCherry, for 
details on plasmid see Kankowski et al., 201835) was performed on the day of culture preparation 
(day in-vitro 1, DIV-1). AAV was applied in small drops on top of the slices using a micro-pipette 
to cover the whole slice. 
Antibody staining and microscopy 
For immunohistochemistry, cultured human slices were fixed for 24 h in 4% paraformaldehyde in 
phosphate buffered saline (PBS, pH 7.3) at 4°C before transfer to a 30% sucrose in PBS 
overnight. Following 3 freeze-thaw cycles using dry ice, slices were incubated in blocking solution 
(PBS, 10% normal donkey serum, 0.5% Triton X-100, 2% milk powder) for 2 h. Slices were 
stained with NeuN (Millipore MAB377, monoclonal, mouse, dilution 1:250) primary antibody 48 h 
at 4°C, followed by several washing steps in PBS and overnight incubation at 4°C with donkey-
anti-mouse Alexa Fluor 488 (dilution 1:500; Invitrogen, Carlsbad CA, USA) secondary antibody. 
Sections were counterstained with the nuclear stain DAPI (10 µg/ml, 15 min) and mounted on 
glass slides with ProLong Gold Antifade Reagent (Life Technologies, Carlsbad CA, USA). 
Confocal images were acquired with an inverted confocal laser scanning microscope LSM700 
(Zeiss, Oberkochen, Germany). Z-stacks were acquired with 0.5 µm lateral and 4 µm axial pixel 
size to identify individual nuclei and cells. A 405 nm laser (set at 2%) was used for excitation of 
DAPI. A 639nm laser (set at 2.9%) was used for detection of NeuN (Cy5). A 555 nm laser (set at 
3%) was used for excitation of mCherry. 
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Data analysis and statistics 
Toxfinder data of high throughput screening were annotated in Microsoft Excel and analyzed 
using Origin 7 G (OriginLab Corporation, Northampton MU, USA)30. 
Electrophysiological data recorded in HEK cells and primary neuronal cell cultures was quantified 
and measured using an IGOR Pro (Version 6.3.7.2, Wavemetrics Inc., Oregon, USA) procedure 
written by Dr. Marcus Semtner (MDC Berlin) and the extension PatchersPowerTools31. 
For analysis of human recordings, signals were band pass filtered (1-1000 Hz) and last 5 min of 
each application (300 s of each application phase) were analyzed with Clampfit 10.7 threshold 
analysis (Molecular Devices, Sunnyvale, CA, USA). All events visually identified as burst activity 
(defined by biphasic, positive and negative deflection and a duration ≥ 100 ms) were manually 
indicated for further analysis of event frequency (inter-event-interval, IEI), amplitude and total 
number of events during the analyzed time frame31. Interictal spikes (defined by exclusive 
negative deflections and a duration <10 ms) were not analyzed. According to literature, interictal 
spikes, although pathologically relevant, are not significantly affected by AEDs36,37.  
Data of patch clamp and field potential recordings were analyzed with GraphPad Prism 5 
(GraphPad Software, Inc., San Diego, CA, USA). Data were subjected to D’Agostino and Pearson 
omnibus normality test and analyzed accordingly. In cases where sample size of tested groups 
was too small for evaluation of data distribution, data was analyzed using non-parametric tests31. 
Details on statistical analysis are described in Kraus et al (2019)31. 
 
5. Results 
Screening for potential edGlyR antagonists (Schneidereit et al., 201730) 
To identify specific edGlyR antagonists, I performed a high-throughput screening with a 
fluorescence-based approach using a chloride-sensitive dye in HEK293T cells overexpressing 
unedited GlyR or edGlyR38,39. I used the NIH Clinical Collection small molecule compound 
libraries (I & II) to test approximately 800 substances for their antagonist potential against edGlyR. 
Although in this first screening line I was unable to validate promising candidates for edGlyRs 
(data not shown or published), we were successful in developing a novel, low-cost 
pharmacological screening tool based on an in house-build automated XY-stage. We published 




Figure 1 Structures of known and possible ligands for edGlyR 
Selected ligands and possible edGlyR targets including positive and negative charges. Carboxyl and ethyl groups are 
marked in red. Ammonium is marked in blue. (A) Substances known to act on edGlyR. (B) Candidates for antagonists 
of edGlyR: dimethylethanolamine, sarcosine and methylamine. IP: isoelectric point. 
While library screens have the advantage to cover a broad spectrum of possible ligands, they do 
not focus on structural similarities of derivatives of known ligands. In a next step, we therefore 
compared chemical structures of GlyR agonists and antagonists (Fig. 1A). More specifically, 
glycine, β-alanine, taurine, GABA, and ammonium are known agonists of GlyR or edGlyR35,40,41, 
whereas histamine was recently identified as an inverse agonist of GlyR and edGlyR42. We 
considered three substances that shared similarities to, and exhibited differences with, known 
edGlyR agonists or antagonists: dimethylethanolamine (DMEA), sarcosine and methylamine 
(Fig. 1B). 
To test the correlation between structural similarities of potential edGlyR ligands and their 
function, we assessed the effects of DMEA, methylamine and sarcosine on edited and non-edited 
GlyR currents. For this purpose, we performed whole-cell patch clamp recordings in HEK293T 
cells overexpressing edited and non-edited homomeric α2B or α3L GlyR, which are prevalent 
edGlyR variants in TLE18. In all investigated cells, glycine evoked stable current responses with 
a peak and a steady-state current component (Fig. 2). During the steady state phase of glycine-
evoked currents, application of up to 25 mM sarcosine or methylamine did not affect GlyR or 
edGlyR activity, independently of the tested subunit (data not shown), suggesting that these two 
compounds do not act as GlyR ligands. For both unedited and edited GlyR α3L and GlyR α2B 
5-10 mM DMEA was able to inhibit glycine evoked currents (Fig. 2).  
Since application of DMEA increased pH of our HEPES buffered extracellular solution (10mM 
DMEA corresponds to ~pH 10), I performed additional experiments with physiological pH 7.4 
using saturating concentrations of DMEA. I found that our initial effect on GlyR and edGlyR 
currents was purely pH dependent, as application of DMEA at physiological pH did not affect GlyR 




Figure 2: Effect of DMEA on activation of unedited and edited GlyR by glycine. 
Activation of all tested edGlyR subunits was blocked by high concentrations DMEA only when pH was not adjusted. Adjusting pH of 
extracellular solutions containing DMEA to pH 7.4, abolished effects on glycine evoked currents in most of the GlyR subunits. (A-D, 
left) Example traces from patch-clamp recordings in HEK cells overexpressing unedited GlyR α3L (A), edGlyR α3L (B), unedited 
GlyR α2B (C) or edGlyR α2B (D). (A-D, right) Ratio of current amplitude before and at the end of DMEA application was normalized 
to ratio of current amplitude without DMEA application (baseline, only glycine) in the same cell. DMEA was applied during steady state 
of GlyR activation by glycine. Scale bars: 0.5 nA, 10 s. mean ± SEM; data is purely descriptive and no statistical analysis was 
performed due to low n in some of the experimental groups. Experiments without adjusted pH were performed by Nikolai Dorka (TU 
Braunschweig, Lab of Prof. Jochen Meier, TU Braunschweig, Germany), control experiments with adjusted pH and data analysis of 
all experiments were performed by me. 
14 
 
Effects of DMEA in neuronal cultures and resected human brain tissue (Kraus et al., 201931) 
DMEA has been applied as therapy for different neurological disorders, though molecular targets 
are still unknown43–48. We therefore continued to investigate in more detail functional mechanisms 
of DMEA action, although we could not confirm the antagonist effect of DMEA on edGlyR currents. 
We first analyzed DMEA effects in primary neuronal cell cultures, to investigate, 1) whether DMEA 
affects spontaneous neuronal activity and 2) affects intrinsic properties of neurons (see Fig. 1 of 
Kraus et al., 201931). Using a buffered solution at a pH of 7.4, we observed a decrease of 
spontaneous neuronal activity without affecting the resting membrane potential (RMP), the latter 
suggesting little effect on intrinsic properties of neurons. We showed full block of spontaneous 
activity at 2 mM DMEA without increased effect at higher concentrations. Due to this promising 
effect on neuronal activity, I investigated potential antiepileptic effects of DMEA in resected human 
brain tissue of TLE patients. 
To investigate DMEA effects on epileptiform activity in resected human brain tissue, I first 
established stable recording conditions for human hippocampal brain slices in our experimental 
setup with a novel submerged type recording chamber. Application of 8mM K+ and 4-AP induced 
two types of activity: interictal spikes and burst activity. Since interictal spikes are considered to 
be insensitive to established antiepileptic drugs, I focused my analysis on burst activity. I was able 
to show fast induction of burst events, which were stable for long periods and in addition sensitive 
to the clinically approved AED lacosamide. Using this established recording procedure, I then 
investigated effects of 5 and 10 mM DMEA on epileptiform activity. I found 5 mM to show only a 
mild effect compared to 10 mM DMEA in tissue of the first six patients and continued to apply only 
10 mM DMEA in tissue of the following five patients31. DMEA showed heterologous effects on 
burst activity, ranging from no effect to a full block of activity in three patients. Overall, DMEA 
significantly decreased the number of burst events exhibiting antiepileptic effects in most slices 
(see Fig. 4A of Kraus et al., 201931). 
 
C-to-U RNA editing tool in human brain slice cultures (Le Duigou et al., 201833) 
edGlyR function can have a bimodal effect on the neuronal network, depending on neuronal cell 
type inflicted with edGlyR expression19,26. Unfortunately, so far little is known about the expression 
pattern of edGlyR in TLE patients. To further investigate C-to-U RNA editing on single cell level, 
I aimed to apply a recently developed RNA-editing sensor (RNAed sensor) tool to human 
organotypic brain slice cultures of TLE patients. The RNAed sensor is capable of identifying 
C-to-U RNA editing on a single cell basis and has been established for cell culture and primary 
neuronal culture systems 35. In cells capable of C-to-U RNA editing, the sensor element will be 
edited to a stop codon. Once the stop codon is introduced to the sequence, the dominant 
cytosol-trafficking sequence is no longer synthesized, leading to translocation of the reporter 
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protein mCherry to the nucleus by the now dominant nucleus targeting domain. For successful 
expression of our RNAed sensor, we used an AAV2/9 viral system for transduction of human 
brain slices. In cooperation with Prof. Richard Miles, I analysed neuronal specificity of our viral 
system in human organotypic brain slice cultures (see suppl. Fig. 1F of Le Duigou et al., 201833). 
In the first set of experiments, I was able to show specific neuronal expression of the RNAed 
sensor in human neurons as visible by co-localization of neuronal marker NeuN and mCherry 
expression. 
This proof of principle work will enable the use of the RNAed sensor tool to better understand 
mechanisms of C-to-U RNA editing in TLE on single cell level in future experiments. 
 
6. Discussion 
Focal epilepsy is pharmacoresistant in 30-40% of patients4, and all new AEDs which had been 
developed over the last decades did not result in seizure freedom in these patients. Despite the 
abundance of > 20 AEDs, pharmacoresistance in TLE remains a challenge and therefore calls 
for the development of new, individual therapeutic options. 
In the present thesis, I focused on edGlyRs as a potential novel target for individual antiepileptic 
therapy. Using high-throughput screening methods and structural analysis of known GlyR ligands, 
I identified three possible edGlyR antagonists: methylamine, sarcosine and DMEA. While neither 
methylamine nor sarcosine showed any effects on GlyR or edGlyR currents in a heterologous 
expression system, DMEA decreased glycine evoked currents of unedited and edGlyR in a 
concentration-dependent manner. Further control experiments revealed a decrease of GlyR 
activity indirectly by increase of pH affecting cell viability rather than by specific function of DMEA 
on GlyR. Independently of the non-specific effect of DMEA on edGlyR currents, we continued to 
investigate DMEA as a potential antiepileptic molecule. Indeed, DMEA had been investigated as 
a therapy for different neurological diseases in the past43–45,47,48, without detailed knowledge on 
specific targets of action. 
DMEA shares structural similarities with choline and was first hypothesized to be a precursor for 
acetylcholine (ACh). In vivo experiments indeed showed that DMEA increases plasma and brain 
choline, though brain ACh levels remained unaffected49,50. The proposed correlation of DMEA to 
the cholinergic system had led to multiple clinical trials, in which DMEA was tested as treatment 
for tardive dyskinesia (TD)43,44,47. Later, systematic reviews could not confirm positive effects of 
DMEA or other cholinergic compounds in patients with TD46,51, questioning any functional impact 
of DMEA on the cholinergic system. Surprisingly, in both acute and chronic seizure models, a 
conjugate of DMEA and valproate was shown to be more potent compared to valproate alone. 
This may be explained by a DMEA-induced increase in uptake of valproate through the blood 
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brain barrier52. However, Shekh-Ahmad and colleagues did not evaluate the effect of DMEA 
alone, and until now, targets of DMEA action have not been identified. 
We investigated the effect of DMEA on spontaneous activity in untransfected neuronal cultures 
and on epileptiform activity in resected human brain tissue. Indeed, we were able to show a 
decrease of spontaneous activity in neuronal cultures while resting membrane potential and 
action potential threshold remained largely unaffected, suggesting no effect on intrinsic but rather 
synaptic excitability31. In resected human brain tissue, DMEA displayed strong antiepileptic 
effects in the majority of investigated human slices, including a full block of epileptiform activity in 
slices of three out of 11 patients. The observed complete block of activity could not be reproduced 
in tissue of all patients, implying differences in expression patterns of molecular DMEA targets 
among patients.  
In this thesis, I was unable to identify targets of DMEA action, though due to above-mentioned 
similarities with ACh and choline, M2 and M3 muscarinic ACh receptors (mAChRs) present 
potential targets. Choline and Ach have both been identified as M2 and M3 ligands53,54. The Gßy-
subunit of M2 and M3 mAChRs increases the open probability of G-protein coupled inwardly 
rectifying potassium (GIRK) channels, specifically GIRK1 and GIRK4 subunits55. Both GIRK1 and 
GIRK4 are expressed in the hippocampus56–58 and activation of GIRK was described to have 
anticonvulsant effects in vitro and in vivo59. For these reasons, M2 or M3 mAChRs and GIRK 
channels present a possible mechanism for DMEA action and will have to be investigated in more 
detail in future experiments. 
DMEA has been tested in healthy volunteers as well as patients suffering from different 
neurological disorders. First application of DMEA to human healthy volunteers dates back to the 
1960s, when DMEA was reported to exert stimulating effects comparable to amphetamine60,61. 
Murphree et al. (1960) described improved concentration, increased muscle tone and changed 
sleeping habits in healthy males (21-26 years) with an intake of 10-20 mg DMEA (or Deanol) daily 
for 2-3 weeks compared to a placebo group61. Though this observation was subjective and the 
cohort small, they also reported no change in heart rate, body weight, muscle power, hand 
steadiness or vital capacity. In contrast, two double-blinded, placebo-controlled studies reported 
side effects of DMEA in TD patients such as lethargy, drowsiness and a mild but significant 
increase in the schizophrenia score43,44. However, a review comparing multiple studies was not 
able to confirm an increased risk for psychosis in TD patients when treated with DMEA46. In 
addition, severe neurological and cardiovascular side effects (apathy, motor retardation, 
increased confusion associated with rise in systolic and diastolic blood pressure) were reported 
in two AD patients when treated with 1,800 mg DMEA daily48. In contrast to Murphree et al. 
(1960)61, the abovementioned studies reporting severe side effects administered DMEA in a 
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100fold higher daily dosage (1,000-2,000 mg vs. 10-20 mg). The reported side effects of DMEA 
application in patients calls for the need to investigate DMEA action in more detail. 
Although in this thesis, I clearly demonstrate an antiepileptic effect of DMEA, the applied high 
concentrations of DMEA, the variability of underlying pathologies and unknown molecular 
mechanism of action present substantial limitations.  
The applied high concentration of DMEA presents two limitations: first, the observed increase of 
pH in the presented HEK cell experiments. Alkaline shift of pH by 0.2 was reported to increase 
neuronal hyperexcitabilty, in contrast to antiepileptic effects shown by acidic shift62. For this thesis, 
all experiments in neurons and human tissue were performed using bicarbonate buffered aCSF 
with a stable pH of 7.4 and a maximum alkaline shift in pH of 0.2. The clear antiepileptic effects 
of DMEA can therefore not be explained by potential acidic changes of pH. Second, addition of 
DMEA to our extracellular solution increased osmolarity by up to 10 mOsm, possibly affecting the 
observed antiepileptic effect. Previous studies have reported a decrease of neuronal excitability 
and epileptic activity upon application of hyperosmolar solutions (5 mOsm and above). In most 
cases, 30 mOsm and more was necessary to induce these effects63–65. As shown by Rosen and 
Andrew (1990), an increase of extracellular osmolarity by 10 mOsm might result in a 10% 
decrease of EPSC amplitude in CA1 pyramidal neurons, though the effects of such EPSC 
alteration on network activity were not investigated64. I was able to show that an increase in 
osmolarity of the extracellular solution does not result in a decrease of epileptiform activity, 
indicating that the antiepileptic effects of DMEA are not primarily mediated by changes in 
osmolarity31. 
Differences in neuronal survival and the degree of hippocampal sclerosis could possibly 
contribute to the observed interindividual effect of DMEA between patients. Neuronal survival or 
tissue quality could have been influenced differentially by the transportation solutions (NMDG vs 
choline-based aCSF). We cannot exclude differences in neuronal survival depending on transport 
solution, though in all slices included in this project, epileptiform activity was induced within a few 
minutes following the application of 8mM K+ and 4-AP and was stable in most slices, indicating 
no differences in tissue quality between different transport conditions. 
Epileptiform activity is highly variable in frequency, spike pattern and amplitude depending on the 
induction method, recording conditions and recorded brain area. In rodent slices, epileptiform 
activity can be induced by inhibition of potassium channels by 4-AP alone66–68. However, in human 
brain tissue, only application of 4-AP in combination with electrical stimulation or elevated 
extracellular potassium was shown to induce stable epileptiform activity31,69,70. Gabriel et al. 
(2004) showed a high variability of epileptiform activity between patients, with highest occurrence 
of seizure-like events in the dentate gyrus of patients with hippocampal sclerosis69. In this study 
by Gabriel and colleagues and in other studies concerning epileptiform activity in resected human 
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brain tissue, field potential recordings were performed using an interface type recordings 
chamber69,71–74. For this thesis, I recorded field potentials using a modified submerged chamber 
and observed mostly burst activity (spike and burst activity) described before as interictal-
like69,72,73,75, in contrast to ictal discharges lasting > 10 s recorded in interface type recording 
chambers. The predictive value of this interictal-like activity for drug development in an ex vivo 
setting is still unclear. Brückner and Heinemann (2000) suggested that only seizure-like ictal 
activity is sensitive to AED application in brain slices (of non-epileptic animals)76. Other studies, 
however, demonstrated a robust decrease in interictal activity in the hippocampus upon AED 
application77–79. In this thesis, I was able to demonstrate stable induction of the observed burst 
activity in all recorded slices and a sensitivity of this burst activity to the approved antiepileptic 
drug lacosamide, indicating that my experimental setting is capable of validating and possibly 
predicting antiepileptic efficacy for drug development. 
In a separate project, I further aimed to investigate the functional mechanisms of edGlyR function 
on TLE. Considering excitatory and inhibitory neurons as the major neuronal populations, two 
effects of edGlyR inhibition are possible as suggested recently80. In case of excitatory neurons, 
edGlyR inhibition could lead to a reduced glutamate release and reduction of hyperexcitability, 
thus acting in an antiepileptic manner19. In contrast, inhibition of edGlyR expressed in inhibitory 
neurons is expected to result in network disinhibition and consequently an increase of epileptic 
activity26. So far, it is not known which neuronal cell type is inflicted with edGlyR expression or 
how edGlyR contribute to epilepsy onset or epileptogenesis. In this thesis, I established a recently 
developed C-to-U RNA editing sensor for the use in human organotypic brain slice cultures. I was 
able to show neuron-specific viral transfection using an AAV2/9 based expression system and a 
ubiquitous promotor for expression of the RNA-editing sensor tool. The RNA-editing sensor tool 
can be useful in the future to identify the neuronal cell type inflicted with C-to-U RNA-editing of 
GlyR mRNA and help to identify the function of edGlyR in TLE in more detail. 
The consistently high rate of pharmacoresistance in TLE and the failure of new AEDs in clinical 
trials increase the need for novel treatment approaches in this common form of epilepsy. Here, I 
demonstrated antiepileptic properties of DMEA in resected hippocampal tissue from TLE patients, 
indicating its potential to act as a novel AED. I propose that research focused on possible new 
antiepileptic mechanisms as well as TLE-associated modification of GlyR-coding gene transcripts 
can be useful for the identification of affected neuron types in pharmacoresistant TLE and may 
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A B S T R A C T   
 
High-content screening microscopy relies on automation infrastructure that is typically proprietary, non- 
customizable, costly and requires a high level of skill to use and maintain. The increasing availability of rapid 
prototyping technology makes it possible to quickly engineer alternatives to conventional automation 
infrastructure that are low-cost and user-friendly. Here, we describe a 3D printed inexpensive open source and 
scalable motorized positioning stage for automated high-content screening microscopy and provide detailed 
step-by-step instructions to re-building the device, including a comprehensive parts list, 3D design files in STEP 
(Standard for the Exchange of Product model data) and STL (Standard Tessellation Language) format, 
electronic circuits and wiring diagrams as well as software code. System assembly including 3D printing 
requires approx. 30 h. The fully assembled device is light-weight (1.1 kg), small (33×20×8 cm) and extremely 
low-cost (approx. EUR 250). We describe positioning characteristics of the stage, including spatial resolution, 
accuracy and repeatability, compare imaging data generated with our device to data obtained using a 
commercially available microplate reader, demonstrate its suitability to high-content microscopy in 96-well 
high-throughput screening format and validate its applicability to automated functional Cl−- and Ca2+-imaging 
with recombinant HEK293 cells as a model system. A time-lapse video of the stage during operation and as part 







Over the past two decades, automated high-content screening (HCS) 
microscopy has become an indispensable method in cell biology with 
applications in an almost infinite variety of scientific fields including 
cancer research and neurosciences. 
Conventional HCS systems are typically made up of a fully auto- 
mated inverted microscope as a central component and a motorized 
stage mounted on top of the microscope's chassis. The microscope, 
usually equipped with exchangeable objectives, focusing mechanics, a 
digital camera and infrastructure allowing for fluorescence or lumines- 
cence microscopy, is used for visualization of biological probes at the 
microscopic level. The motorized stage enables inspection of specimen 
larger than the field of view of the objective and automatic positioning 
of biological samples, cultured e.g. in multititer plates, during opera- 
tion in high-throughput screening mode. Besides these components, 
 
conventional HCS devices are equipped with additional parts, such as 
an incubator, capable of maintaining optimal conditions necessary for 
culturing cells, liquid-handling systems or robotics for operation in 
almost autonomous high- or ultrahigh-throughput screening mode. 
Commercially available motorized positioning stages are character- 
ized by high-speed scanning capabilities and high positional accuracy 
in the micro- or sub-micrometer range, achieved through e.g. stable 
closed-loop control systems. These stages are claimed ideal for 
manually or automatically positioning a wide range of specimens and 
samples in many types of microscopy or imaging techniques and 
applications but are typically proprietary and  thus  disadvantageous 
for a number of reasons. First, installation of commercially available 
positioning devices or integration with existing equipment as well as 
application and maintenance requires a high level of product-specific 
skill and hence, is resource-intensive and not user friendly or straight- 
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often limited at both hard- and software levels, e.g. because available I/ 
O (input/output) ports are not documented and thus, virtually not 
available to users, software code is closed source or the command set is 
not provided. Third, customization of conventional positioning stages is 
hampered for the sake of protection of proprietary hard- and software. 
For example, hardware modification is typically not permis- sible and 
will result in the loss of the warranty and exclusion of liability. 
Furthermore, proprietary commercial systems are typically cost-inten- 
sive and not readily applicable to a broad range of laboratories in low- 
resource settings or for educational purposes, e.g. in schools or 
universities. 
Despite the fact that there are examples on low-cost 3D printed 
technologies for cell-based high-content imaging (Campbell et al., 
2014; Walzik et al., 2015; Wardyn et al., 2015) and high-throughput 
screening (Berg et al., 2015; Gregory and Veeman, 2013; Spivey et al., 
2014), a positioning stage for automated high-content screening 
microscopy that is fully open source, scalable and low-cost has not 
been reported yet. The recent availability of rapid prototyping technol- 
ogy, including 3D desktop printing, open source microcontroller 
boards and inexpensive consumer electronics, mechanics and robotics 
parts - also adopted by the ‘Maker’ movement, a culture of do-it- 
yourself (DIY) product design (Editorial, 2013; Landrain et al., 2013; 
Seyfried et al., 2014) - makes it possible to quickly engineer and share 
user-friendly equipment of reduced cost and complexity. 
To overcome the limitations of proprietary technology described 
above we aimed to develop a motorized stage based on a ‘Makers’ 
approach that is fully open source, customizable, robust, affordable to 
a broad range of research labs and could rapidly and easily be re-built 
e.g. in so called fab labs (fabrication laboratories) and - at the same 
time - is sufficiently accurate for automated high-content screening 
microscopy. To this end we aimed to use off-the-shelf electronic 
components as well as 3D-desktop printing and low-cost open-source 
microcontroller architecture, both being increasingly used in the 
development of scientific devices (D'Ausilio, 2012; Frame and Leach, 
2014; Leeuw et al., 2013; Pineño, 2014; Schubert et al., 2013; 
Starosolski et al., 2014; Stokes et al., 2013;  Wittbrodt  et  al., 2014) 
and proven valuable in the design of technology suitable to educational 
purposes (Marzullo and Gage,  2012;  Shannon  et  al.,  2014;  Walzik  
et al., 2015). We further aimed to evaluate the stage with regard to its 
positioning characteristics including spatial resolution, accuracy and 
repeatability and to provide one example each for applications in 
cancer research and in neurosciences i.e. for high-content imaging in 
high-throughput screening mode, e.g. for cell fitness screening, and for 
functional imaging of ion channels, respectively. 
In cancer research, high-content imaging in high-throughput 
screening mode is applied for example in the context of cell viability 
or fitness screening to identify novel chemotherapeutics. Cellular 
fitness is indicated by various physiological indicators which are 
partially and indirectly assessable using fluorescence-based assaying 
methods and is often measured by quantifying cell number using e.g. 
fluorescent proteins (Gilbert et al., 2011). In order to demonstrate the 
applicability of the motorized stage to quantifying cellular fitness, we 
intended to apply the technology with recombinant human embryo- 
derived (HEK293YFPI152L) cells, stably expressing YFPI152L, an en- 
gineered variant of yellow fluorescent protein (YFP) and to compare 
data obtained from the custom device with data from a commercial 
high-end microplate reader. 
In neuroscience, high-content imaging, also referred to as func- 
tional imaging, has become an integral part for evaluating the 
biophysical and pharmacological properties of ion channels - pore- 
forming membrane proteins involved in most physiological and disease 
processes and considered highly attractive drug targets for therapeutic 
intervention  (Alexander  et al., 2015;  Braat and Kooy, 2015;  Meier  
et al., 2014; Ortega-Guerrero et al., 2016; Talwar et al., 2013). In 
functional imaging experiments, the activity of ion channels is mostly 
assessed indirectly using ion-selective indicators such as loadable or 
genetically encoded fluorescence dyes that report an ion channel- 
induced change in intracellular ion concentration via varying fluores- 
cence intensity. For assessing the suitability of the low cost device for 
functional imaging of ion channels, we aimed to conduct agonist and 
antagonist concentration-response experiments with glycine receptor 
(GlyR) chloride channels in combination with YFPI152L as fluores- 
cence probe and with transient receptor vanilloid receptor type 1 
(TRPV1) cation channels in combination with Fluo-4 AM as fluores- 
cence indicator. 
GlyRs are ligand-gated ionotropic receptors that mediate inhibitory 
neurotransmission in the central nervous system and conduct an anion 
current, mainly carried by chloride (Cl−) upon activation by the amino 
acid glycine. The channels can be selectively blocked by the high- 
affinity competitive antagonist strychnine (Lynch et al., 1997). 
Functional GlyRs are formed from a total of five subunits (α1– α4, β) 
which assemble either as α homomeric or αβ heteromeric channels 
(Lynch, 2009). GlyR-activation can be monitored by fluorescence 
imaging using YFPI152L. YFPI152L, an engineered variant of YFP  
with greatly enhanced anion sensitivity, is quenched by small anions 
and is thus suited to reporting anionic influx into cells (Galietta et al., 
2001). It has proven useful in screening compounds against many 
chloride channel types (Balansa et al., 2010, 2013a, 2013b; , 2011, 
2009c; , 2011, 2009c; Kruger et al., 2005; Kuenzel et al., 2016). 
TRPV1 is a non-selective cation channel that mediates pain 
perception in nociceptive somatosensory neurons. It is activated by 
temperatures exceeding 43 °C, by a drop in pH below 6.8 and by 
capsaicin, the main pungent ingredient in chili peppers (Caterina and 
Julius, 2001). When activated, the channels conduct a depolarizing 
cation current, partly carried by Ca2+, leading to an increase in 
intracellular calcium concentration [Ca2+]i. Capsaicin-induced activa- 
tion is antagonized by the competitive antagonist capsazepine, a 
synthetic analogue of capsaicin (Bevan et al., 1992). Activation of 
TRPV1 and increase of the intracellular Ca2+ concentration [Ca2+]i can 
be assessed using Ca2+ selective fluorophores, such as Fluo-4 AM. Fluo- 
4 AM is a non-ratiometric, high-affinity fluorescent dye for quantifying 
[Ca2+]i within a large dynamic range, around a Kd(Ca2+) of 345 nM 
(Gee et al., 2000). Its fluorescence intensity increases with increasing 
[Ca2+]i. 
Finally, we aimed to create and to provide detailed step-by-step 
instructions to re-building the stage and to evaluate it with regard to 
the time required for production and installation. 
 
2. Materials and methods 
 
2.1. Pharmacological reagents 
 
Glycine, strychnine, capsaicin and capsazepine were obtained from 
Sigma-Aldrich. Glycine was prepared as a 1 M stock in water, strych- 
nine was prepared as 10 mM stock in dimethylsulphoxide (DMSO). 
Capsaicin and capsazepine were prepared as 100 mM stocks in DMSO. 
All stocks were frozen at −20 °C. From these stocks, solutions for 
experiments were prepared on the day of recording. 
 
2.2. Calcium indicator 
 
Fluo-4 AM was obtained from Molecular Probes and was prepared 
as 10 mM stock in DMSO. Fluo-4 AM stocks were frozen at −20 °C. 
From these stocks, solutions for calcium imaging experiments were 
prepared on the day of recording. 
 
2.3. Cell lines 
 
Human embryonal kidney-derived cells (HEK293, CRL-1573) were 
purchased from The American Type Culture Collection (ATCC). The 
HEK293YFPI152L cell line was generated as described in (Walzik et al., 
2015). 
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2.4. Cell culture 
 
Cells were maintained in DMEM (Invitrogen) supplemented with 
10% fetal bovine serum (Biochrom) and penicillin (100 U/ml)/strep- 
tomycin (100 mg/ml) (Invitrogen) and were cultured in T75 flasks 
(TPP) at 37 °C, 5% CO2 in a humidified incubator according to 
standard procedures. Cells were passaged every 2–3 days and used in 
experiments when approximately 80–90% confluent. 
 
2.5. Low-cost 3D printed stage 
 
The stage in its current design is made up of a total of sixteen 3D 
printed parts (14 individual designs), two orthogonally positioned 
bipolar stepper motors (200 Steps/Rev, NEMA 8, Watterott, 
Germany) each attached to a threaded spindle with lead screw (1 mm 
pitch, Misumi, Japan) and terminally centered using ball bearings 
(Kugellager Shop, Germany), six linear bearings (Misumi, Japan), four 
M4 brass guide rods (OBI, Germany), two pairs of end switches (ZF 
Electronics, Germany) and a total of 65 standard M2-4 screws and 
nuts. The stepper motors are controlled via L293DNE H-bridge motor 
drivers (Texas Instruments, USA) mounted to a custom created 
Arduino UNO-compatible actuator shield, i.e. a printed circuit board 
(PCB), designed in Fritzing 0.9.2b/64 bit (Interaction Design Lab 
Potsdam, Germany) which plugs directly into Arduino UNO pin- 
headers. To limit the traveling path of the stage and to allow zero- 
point calibration at the start of an experiment each of the two axes is 
equipped with a pair of end switches (ZF Electronics, Germany) 
connected to the shield. 
The stage is orchestrated by one Arduino UNO open-source 
electronics prototyping board (Arduino, Italy) based on the 
ATmega328 microcontroller programmed using the Arduino open- 
source integrated development environment (IDE). The NI LabVIEW 
Interface for Arduino Toolkit (National Instruments, Ireland) was used 
for interfacing the Arduino board with LabVIEW 2014 through a serial 
connection. A user interface for parametrization, calibration and 
application  of the  device was written in LabVIEW  2014 for  use with  
a standard laptop or personal computer with e.g. Windows 7 operating 
System (Microsoft Corporation, USA) or any other device running 
LabVIEW software. 
 
2.6. Custom built robot 
 
The imaging system is made-up of an autosampler for liquid 
handling (HTS PAL, CTC Analytics, Switzerland), a miniaturized low- 
cost inverted digital fluorescence microscope (Thorlabs, USA) with 10x 
objective (Olympus, Japan), CCD camera (Point Grey Research Inc., 
USA) and LED light source (LUMITRONIX, Germany) and in house 
built autofocussing mechanics - all orchestrated by Arduino (Arduino, 
Italy) and LabVIEW software (National Instruments, Ireland). 
 
2.7. Preparation of cells for Example I experiments 
 
The day before imaging experiments HEK293YFPI152L cells, pre- 
viously dislodged from a T75 flask (TPP, Switzerland) using 0.25% 
trypsin–EDTA solution (Gibco BRL) and resuspended into DMEM, 
were counted using a haemocytometer (LO Laboroptik GmbH, 
Germany) and were seeded into the wells of a 96-well plate at 5000 
(row A–H, column 1–2), 10000 (row A–H, column 3–4), 15000 (row 
A–H, column 5–6), 20000 (row A–H, column 7–8), 25000 (row A-H, 
column 9–10) and 30000 (row A-H, column 11–12) cells per well in 16 
replicates each. Cells were cultured overnight at 37 °C, 5% CO2 in a 
humidified incubator according to standard procedures. The next day, 
the medium was replaced by 50 μl standard control solution, which 
contained (in mM) NaCl 140, KCl 5, CaCl2 2, MgCl2 1, HEPES 10, and 
glucose 10 (pH 7.4, NaOH) and fluorescence intensity of cells was 
measured  first  using a VICTOR X4 plate reader (Perkin Elmer) with 
YFP filter set (exposure time: 0.5 s) and subsequently using the custom 
built robot. 
 
2.8. Example I experiments with custom built robot 
 
The 96-well plates were placed onto the 3D printed motorized stage 
of the in house-built imaging system and cells were imaged with a 10× 
objective (Plan Achromat, 0.25 NA, 10.6 mm WD, Olympus, Japan). 
Illumination from an LED (Nichia NCSE119A 98 lm, LUMITRONIX 
LED-Technik GmbH) passing through an excitation filter (EX 497/16, 
MDF-YFP, Thorlabs) and fluorescence light passing through emission 
and dichroic filters (BA 535/22, DM 515, MDF-YFP, Thorlabs) was 
imaged by a CCD camera (1.3 MP Chameleon, 1/3" CCD, Point Grey 
Research Inc.) and digitized to disk onto a personal computer with 
Windows operating System (Microsoft Corporation). The primary 
resolution of the camera was 1280×960 pixel, although images were 
binned (2×2), resulting in a resolution of 640×480 pixels. Each image 
typically contained 50–250 cells.  The CCD image acquisition time was 
2 s. These experiments were conducted at room temperature. 
 
2.9. Transient transfection of HEK293 cells for Example II 
experiments 
 
Approx. 24 h prior to transfection, cells were seeded into 6 cm 
dishes (TPP) at a concentration of 106 cells per dish. GlyR chloride 
channel subunits (Kuhse et al., 1990; Legendre et al., 2009), YFPI152L 
(Galietta et al., 2001) and TRPV1 were transfected with a total cDNA 
quantity of 4 µg per 6 cm dish. Cells were transfected using 30 μl 
PolyFect Transfection Reagent (Qiagen) according to the manufac- 
turer's instructions. We have published a detailed comparison of five 
transient transfection methods employed routinely for this purpose 
(Gilbert et al., 2009a). 
 
2.10. Preparation of cells for Example II experiments 
 
Following termination of transfection, cells were trypsinized by 
adding 0.3 ml of 0.25% trypsin–EDTA solution (Gibco BRL), resus- 
pended into DMEM, and 3×104 cells, suspended in 200 μl DMEM, and 
were plated into each well of a transparent 96-well plate (TPP) for 
fluorescence imaging experiments. Cells were used in experiments 24 h 
later. Individual wells typically contained 3–5×104 cells at the time of 
the experiment. Approximately 1 h prior to commencement of experi- 
ments, culture medium in 96-well plates was entirely removed by 
turning the plate upside-down onto a stack of tissue and plates were 
left for approximately 30 s until culture media was entirely removed 
from the wells. The medium was replaced by 50 μl standard control 
solution, which contained (in mM) NaCl 140, KCl 5, CaCl2 2, MgCl2 1, 
HEPES 10, and glucose 10 (pH 7.4, NaOH) upon washing the cells 
once in 50 μl standard control solution. 
For chloride imaging experiments, the agonist NaI test solution was 
supplemented with 3 mM glycine and serially diluted with NaI test 
solution to obtain agonist solutions containing 3, 10, 30, 100, 300, 
1000 and 3000 µM final glycine concentration. For antagonist con- 
centration response experiments with GlyR α3 expressing cells, the 
control solution was supplemented with 0.1, 0.3, 1, 3, 10, 30, 100 µM 
final strychnine concentration and pre-incubated prior to functional 
imaging for approx. 30 min. 
For calcium imaging experiments, cells were incubated in 50 μl 
standard control solution supplemented with 1 µM Pluronic F-127  
(Life Technologies) and 5 µM Fluo-4 AM (Molecular Probes) final 
concentrations for 1 h at 37 °C, 5% CO2 and staining solution was 
replaced by 50 μl control solution. For TrpV1 receptor stimulation, the 
control solution was supplemented with 0.1, 0.1, 1, 10, 100, 1000, 
10000 and 100000 nM final capsaicin concentrations. For TRPV1 
antagonist concentration response experiments, the agonist solution 
containing 1 µM capsaicin was supplemented with 0.01, 0.1, 1, 10, 100, 
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1000 and 10000 nM capsazepine (Sigma) final concentration. For 
TrpV1 receptor stimulation, the control solution was supplemented 
with 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 and 3000 µM final 
capsaicin concentrations. 
All drugs were diluted from stocks at the day of the experiment and 
experiments were conducted at room temperature. 
 
2.11. Example II experiments 
 
Imaging experiments were conducted as explained in section 
Example experiments I with the difference that the experimental 
protocol involved imaging each well twice: once in 50 μl control 
solution and once 8 s after the injection of 100 μl agonist solution. 
Liquid handling was performed with the autosampler described above. 
Solutions were applied to cells at a rate of 0.6 ml/min. 
 
2.12. Evaluation of positioning characteristics 
 
Images acquired for calculation of spatial resolution, accuracy and 
repeatability were aligned with ImageJ (National Institutes of Health) 
using the plugin Register Virtual Stack Slices (Arganda-Carreras et al., 
2006) (for documentation see http://fiji.sc/wiki/ 
Register_Virtual_Stack_Slices). Bi-directional registration information 
(in pixels) was extracted from so called transforms *.xlm-files provided 
by the plugin and converted into micrometers based on a previously 
determined factuator. The conversion factuator was calculated from 
images of a 1951 USAF test target consisting of reference line patterns 
with well-defined dimensions. 
 
2.13. Image registration 
 
Images acquired with the automated high-content screening 
system were spatially aligned with LabVIEW (National Instruments) 
and ImageJ (National Institutes of Health) using the plugin Register 
Virtual Stack Slices (Arganda-Carreras et al., 2006). For automated 
registration of large sets of image pairs, we created a LabVIEW virtual 
instrument (VI) which dynamically generates jython scripts and calls 
the Register Virtual Stack Slices plugin via the command line in 
ImageJ headless mode in a non-interactive fashion. Resulting trans- 
forms are saved in XML format and are used by the VI for extraction of 
matching image regions in the original image pairs which are copied to 
a new subdirectory in TIFF format and enable single cell or image- 
based quantitative image analysis. 
 
2.14. Single cell-based quantitative image  analysis 
 
Registered images of fluorescent cells were segmented and quanti- 
tatively analyzed using a modified version of DetecTiff software (Gilbert 
et al., 2009b). The fluorescence signal of identified cells was measured 
in images acquired before and after the addition of agonist solution as 
the mean of all pixel values within the area of a cell. ‘% fluorescence 
quench’ in chloride imaging experiments is defined as: 
(1)% fluorescence quench =(Finit – Ffinal) *100/ Finit. 
and ‘% fluorescence change’ in calcium imaging experiments is 
defined as: 
(2)% fluorescence change =(Ffinal / Finit) – 1*100, 
where Finit and Ffinal are the initial and final values of fluores- 
cence, respectively. 
 
2.15. Image-based intensity analysis 
 
Mean fluorescence intensity (MPI) of all pixels within one image 
acquired with the custom-designed automated high-content screening 
system was quantitatively analyzed using a modified version of 
DetecTiff software. 
2.16. Calculation of concentration-response relationships 
 
Individual concentration responses were constructed by pooling 
results from approx. 100–300 cells in one well exposed to agonist 
solution. Concentration-response relationships were fitted with the 
following equation: 
(3)F = Finit /(1+(EC50 /[Agonist])nH). 
where F is the fluorescence corresponding to a particular agonist 
concentration, [Agonist]; Finit is the initial fluorescence value; EC50 is 
the concentration that elicits half-maximal activation; and nH is the 
Hill coefficient. Curve fits were performed using a least squares fitting 
routine (Origin 7 G, OriginLab Corporation). All averaged results are 
expressed as mean ± SD. 
 
2.17. Data analysis and visualization 
 
Plate reader data were annotated in Microsoft Excel and analyzed 
using Origin 7 G (OriginLab Corporation). Heat maps of normalized 




We have developed an inexpensive motorized positioning stage that 
can easily be reconstructed within a few hours using 3D desktop 
printing and off-the-shelf components. To demonstrate its applicability 
to automated high-content microscopy in high-throughput screening 
mode, we integrated the stage into a custom built imaging robot (see 
Methods for details). Schematics and images of the stage as well as of 
the robot are shown in Fig. 1. We describe positioning characteristics of 
the stage, including spatial resolution, accuracy and repeatability, 
compare imaging data generated with our platform to data obtained 
using a commercially available microplate reader, demonstrate its 
suitability to high-content microscopy in 96-well high-throughput 
screening format and validate its applicability to automated functional 
Cl−- and Ca2+-imaging with recombinant HEK293 cells as a model 
system. We further provide detailed step-by-step instructions to re- 
building the stage including a comprehensive parts list, 3D design files, 
electronic circuits and wiring diagrams as well as software code, and we 
give examples for customization, e.g. for use with various culture 
plastic ware such as 40 and 60 mm dishes, T25 and T75 tissue culture 
flasks and standard 76×26 mm (3×1 in.) microscope slides. System 
assembly including printing of plastic parts requires approx. 30 h. The 
fully assembled device is light-weight (1.1 kg), small (33×20×8 cm) 
and extremely low-cost (approx. EUR 250). A time-lapse video of the 
stage and custom built robot during operation can be found at https:// 
vimeo.com/158813199. 
 
3.1. 3D-design, mechatronics, software & development process 
 
As a starting point towards designing a low-cost positioning stage 
we modified a miniaturized and motorized webcam-microscope stage 
previously developed in our lab (Walzik et al., 2015) to fit the 
dimensions of a standard, e.g. 24-, 96-, 384- or 1536-well multititer 
plate using commercial computer assisted design (CAD) software 
(Autodesk Inventor 2013, Autodesk, Inc., USA). In a next step, we 
optimized the design to ensure robustness in everyday use, and at the 
same time, minimize space and resource requirements. Images of the 
initial and modified up-scaled stages, respectively, are shown in Fig. 1a 
and b-d, demonstrating the versatility of 3D printed infrastructure with 
regard to customization. The stage in its current design is made up of a 
total of sixteen 3D printed parts (14 individual designs), printed during 
an overall time of < 23 h from approx. 250 g black acrylonitrile 
butadiene styrene filament (ABS, MakerBot Industries, USA) using a 
consumer grade 3D printer (MakerBot Replicator, MakerBot 
Industries, USA). For details on the mechanical and electronic compo- 
nents please refer to the methods section. 
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Fig. 1. The open source motorized microscope stage is customizable and can be modified to fit any conventional or custom assembled hardware. (a) Previously developed low-cost stage 
for a motorized webcam-based digital microscope serving as a starting point for designing the low-cost open source positioning system. Scale bar: 2 cm. (b) Assembly drawing of the 
stage indicating its simple design and modifiability. Scale bar: 5 cm. (c) Close-up view of the stage, integrated into a custom built screening robot. (d) Custom built screening robot with 
integrated stage. 
 
The stage is orchestrated by one Arduino UNO open-source 
electronics prototyping board (Arduino, Italy), the NI LabVIEW 
Interface for Arduino Toolkit (National Instruments, Ireland) and 
LabVIEW 2014 through a serial connection. The device was prototyped 
during a period of approx. 6 months, which can be divided into three 
phases. In the initial phase (2 months), the required electronic 
components were researched, ordered and assembled and preliminary 
circuits and software were developed. In the second phase (1 month) 
the motorized stage was engineered and proof-of-concept experiments 
were carried out and in the final stage (3 months), hard- and software 
were optimized and benchmarking with conventional technology was 
conducted. 
All mechanical and electronical hardware components, 3D design 
files, PCB sketch and software code as well as additional information 
required to re-building and applying the stage are summarized in the 
Supplementary Table S1. 
 
3.2. Positioning characteristics 
 
The usability of a motorized positioning system for microscopic 
applications is limited by a variety of parameters, including (1.) its 
overall travel range, (2.) its spatial resolution, i.e. the smallest traveling 
distance of the positioning stage in X- and Y-direction, (3.) its accuracy, 
the difference between the actual position in space and the position 
as quantified by a measurement device and (4.) its repeatability, i.e. the 
range of positions attained when the system is repeatedly commanded 
to one location under identical conditions (Conrad et al., 2000). 
Generally speaking, the larger the travel range, the smaller the spatial 
resolution; the higher the accuracy and the better the repeatability, the 
larger is the spectrum of potential applications. In the current config- 
uration, the travel range is approx. 120×80 mm. The spatial resolution 
of the positioning stage is defined by the following equation. 
(4) X,     Y     Resolution     (µm)=Pitchspindle/No.      of stepsmotor,where 
Pitchspindle is the incline  of  the  spindle  per revolution (1000 µm) 
and No. of stepsmotor is the total number of steps per revolution of the 
stepper motor (200 steps). To evaluate whether the calculated spatial 
resolution of 5 µm equals the practical resolution, we set the control- 
ling software to repeatedly move one axis by a single step and to 
subsequently acquire an image of an USAF 1951 test target. This 
procedure was repeated 50 times for both axes in positive and negative 
direction each. The practical resolution was quantified by measuring 
the drift of the USAF 1951 test target-structures in recurrently 
acquired images using the ImageJ plugin Register Virtual Stack. For 
methodological details refer to methods section. The relation of set 
point positions to associated measured positions for both axes is 
displayed in the graphs in Fig. 2A and B (X-axis, black; Y-axis, grey). 
From these data, we calculated the average step size (n = 50, mean ± 
SD,) for positively and negatively directed movements of the X- (5.1 ± 
1.8 µm; −4.9 ± 1.9 µm) and Y-axis (3.5 ± 2.2 µm; −5.0 ± 1.1 µm), re- 
spectively, as shown in the histogram insets in Fig. 2a and b. The grey 
(Y-axis) and black (X-axis) dots in Fig. 2a and b, respectively, represent 
measured positions of the axis perpendicular to the actively moving 
axis and indicate a passively occurring offset that was not further 
quantified. 
These results demonstrate excellent correlation of practical resolu- 
tion to calculated theoretical resolution but at the same time also reflect 
moderate accuracy as indicated by the high standard deviation (X: ± 
1.8 and ± 1.9 µm; Y: ± 2.2 and ± 1.1 µm) at the resolution limit of the 
stage as well as a passively occurring offset at the axis perpendicular to 
the actively moving axis. 
For assessing repeatability of the stage, we parametrized the 
controlling software to repeatedly capture a single image at the same 
position of a USAF 1951 test target, defined by a fixed number of steps 
(well D4 of 96-well plate, corresponding to 6900 and 6200 single X- 
and Y-axis motor steps, respectively) to be executed by the stepper 
motors upon zero-point calibration. The repeatability was quantified by 
measuring the deviation from the original position using the ImageJ 
plugin Register Virtual Stack. Fig. 2c shows single data points and box 
plots of the deviation from the original position in X- and Y-direction. 
The  minimal  and  maximal  deviations  from  the  origin  vary between 
−92.6 and 94.5 µm for the X-axis and −29.2 and 108.8 µm for the Y- 
axis. The average repeatability and standard deviation for X-(black, 3.9 
± 48.3 µm) and Y-directions (grey, 5.4 ± 28.9 µm) calculated from a 
total of 19 repeats each are represented by open circles and error bars. 
477  
D.  Schneidereit et al. Biosensors and Bioelectronics 92 (2017) 472–481 
 
Fig. 2. The spatial resolution, accuracy and repeatability of the positioning system is sufficient to microscopic applications. (a) and (b) Correlation plots of set point position to 
associated measured position of the X- (black) and Y-axis (grey) when either the X- (a) or Y-axis (b) is moved. The histogram-insets depict the average resolution (mean ± SD, n=50) and 
reflect moderate accuracy as indicated by high standard deviation as well as a passively occurring offset at the axis perpendicular to the actively moving axis (see grey dots in (a) and 
black dots in (b)). (c) The bi-directional repeatability range was assessed by repetitively commanding the device to the same location and measures approx. ± 5 µm. 
 
The solid line in the box mark the median value, upper and lower box- 
margins indicate 75th and 25th percentiles, respectively. 
These data demonstrate the suitability of the stage to microscopic 
applications which require a mean bi-directional repeatability range of 
approx. ± 5 µm. 
 
3.3. Example I (Cancer research): high-throughput cell viability 
screening 
 
In order to assess the applicability of the presented positioning 
device to automated high-content microscopy in high-throughput 
mode, we imaged HEK293YFPI152L cells, recombinantly expressing a 
cytosolic fluorescence marker and seeded at densities between 5000 
and 30,000 cells per well with our custom built robot and compared 
quantification data of cell number to those generated with a microplate 
reader. Plate reader-based quantification typically delivers low-resolu- 
tion data within short time (here: approx. three minutes per 96-well 
plate), i.e. a single data point per well of a multititer plate that is 
usually expressed as relative fluorescence unit (RFU). Microscopy- 
based quantification is more time consuming (here: approx. one hour 
per 96-well plate) but in turn provides data of high content and allows 
characterization of fluorescence signal and cell number at both single 
cell and population-based level, typically expressed as cells per image or 
mean pixel intensity (MPI). Fig. 3a shows images of HEK293YFPI152L 
cells acquired using the custom built system. Fig. 3b shows color maps 
of data generated with the plate reader (left) and the custom robot 
(middle, right) with cold and warm colors representing low and high 
values, respectively. For quantification of the cells per image and MPI, 
images were segmented and quantitatively analyzed using a modified 
version of DetecTiff software (see methods section for details). Fig. 3c 
and d show correlation plots of averaged values for 5000, 10000, 
15000, 20000, 25000 and 30000 seeded cells per well (n =16 wells, 
error bars: ± SD) reflected by RFU from plate reader-based quantifica- 
tion  (11024 ± 233, 13343 ± 606, 16120 ± 1630, 18377 ± 1402, 20385 
± 1207 and 22776 ± 1912) versus MPI (9.9 ± 0.7, 12.8 ± 1.6, 15.4 ± 1.1, 
18.6 ± 1.1, 20.9 ± 1.6 and 21.4 ± 2.3) and cells per image (94 ± 25, 235 
± 43, 366 ± 39, 520 ± 50, 590 ± 53 and 604 ± 74) calculated from data 
obtained using the custom built robot. Regression analysis (dashed 
lines) of quantification data obtained with the custom built system 
including the low-cost positioning stage revealed excellent correlation 
with data from conventional technology  (Fig.  3c,  R2=0.98 ± 0.79; 
Fig. 3d, R2=0.97 ± 47.8). Thus, data generated in high-throughput 
screening experiments using our platform compares well with data 
from conventional technology. 
These results clearly demonstrate that the low cost positioning 
device is suitable to application for high-content imaging in high- 
throughput screening mode. 
 
3.4. Example II (Neurosciences): high-content functional chloride- 
and calcium-imaging 
 
In order to assess whether the motorized stage as a key element of 
our custom built robot enables fluorescence-based functional imaging of 
ion channels in high-throughput mode, we conducted automated 
agonist and antagonist concentration-response experiments with gly- 
cine receptor (GlyR) chloride channels and transient receptor potential 
vanilloid receptor type 1 (TRPV1) cation channels using the fluores- 
cence indicators YFPI152L and Fluo-4 AM, respectively. 
For Cl− imaging experiments with GlyRs, we co-transfected 
HEK293 cells with YFPI152L and α3 GlyR cDNA and seeded the cells 
at defined density of 3×104 cells in each well of a 96-well plate. The 
next day and approximately 1 h prior to imaging, the culture medium 
was completely removed and was replaced by 50 μl NaCl control 
solution. The standard NaCl control solution contained  (in  mM): 
NaCl 140, KCl 5, CaCl2 2, MgCl2 1, HEPES 10, glucose  10,  pH  7.4 
using NaOH. The 96-well plate was placed onto the motorized stage of 
our in house-built imaging system and cells were imaged once in 
control solution or in control solution supplemented with increasing 
concentrations (0.1–100 µM) of the competitive antagonist strychnine 
(STR) to record cellular YFP fluorescence in unquenched state. As 
YFPI152L is almost insensitive to chloride, its fluorescence intensity is 
highest in NaCl solution allowing for optimal focussing into the optical 
layer of cells. Subsequently, cells were perfused with 100 μl NaI test 
solution containing either increasing (3–3000 µM, Fig. 4a) or a single 
concentration of glycine (GLY, 65 µM, Fig. 4b) and were imaged again. 
The NaI test solution was similar to NaCl control solution except that 
the NaCl was replaced by equimolar NaI. Fluorescence quench was 
calculated at single cell level by quantitative analysis of image pairs as 
described in the methods section. Sample images of HEK293 cells 
transfected with both YFPI152L and the GlyR α3 subunit are shown in 
Fig. 4a and b. Average (mean ± SD) agonist and antagonist dose– 
responses were constructed by pooling results from wells exposed to 
different solutions and subsequent averaging from replicate experi- 
ments (Fig. 4a: n =8; Fig. 4b: n =3). Calculated half-maximal activation 
or inhibition concentration (EC50, IC50) for glycine (63.7 ± 7.3 µM) and 
strychnine (3.3 ± 0.7 µM) correspond well with data from functional 
Cl− imaging and electrophysiology previously reported in the literature 
(Meier et al.,  2005; Talwar et al.,  2013)  and  demonstrate  that  the 
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Fig. 3. High-content imaging data acquired in high-throughput screening mode compare well with data from conventional technology. (a) Images of HEK293YFPI152L cells seeded at 
different densities and acquired using the custom built system. Scale bar: 200 µm. (b) Color maps of data generated with a plate reader (left, population-based analysis) and the custom 
robot (middle, population-based analysis; right, single cell-based analysis) with cold and warm colors representing low and high values, respectively. (c) and (d) Correlation plots of 
averaged values for cells seeded at different densities (n =16 wells, error bars: ± SD) and regression analysis (dashed lines) of quantification data obtained with the custom built system 
and conventional technology demonstrating that the low-cost positioning device is suitable to application for high-content imaging in high-throughput screening mode. 
 
motorized stage enables automated fluorescence-based functional 
imaging of GlyRs. 
For Ca2+ imaging experiments with TRPV1 channels, HEK293 cells 
were transiently transfected with TRPV1 cDNA and seeded the cells at 
 
defined density of 2.5×104 cells in each well of a 96-well plate. The next 
day and approximately 1.5 h prior to imaging, the cells were incubated 
in Fluo-4 AM calcium indicator as described in the methods section 
and cells were imaged once in control solution using the custom-built 
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Fig. 4. The positioning device enables high-throughput functional Cl− and Ca2+ imaging for evaluating the physiological and pharmacological characteristics of ion channels. (a, left) 
Images of HEK293 cells transiently transfected with GlyR α3 and YFPI152l, incubated in NaCl control solution (top) and NaI test solution containing 100 µM glycine (GLY, bottom). (a, 
right) Dose-response experiment with increasing glycine concentrations. (b, left) Images of HEK293 cells transfected as in (a) but incubated in NaCl control solution containing 100 µM 
strychnine (STR, top) and upon addition of NaI test solution containing 100 µM glycine (GLY, bottom). (b, right) Concentration-response experiment with constant glycine but 
increasing strychnine concentrations. (c, left) Images of HEK293 cells transiently transfected with TRPV1 cDNA, incubated in NaCl control solution (top) and NaCl test solution 
supplemented with 10 µM capsaicine (CAPS, bottom). (c, right) Dose-response experiment with increasing capsaicin concentrations. (d, left) Images of HEK293 cells transiently 
transfected as in (c) but incubated in NaCl control solution (top) and NaCl test solution supplemented with 1 µM capsaicine and 100 nM capsazepine (CPZ, bottom). (b, right) Dose- 
response experiment with constant capsaicine (1 µM) but increasing capsazepine concentrations. These data correspond well to data available in the literature and validate the 
applicability of the positioning stage as a central and key component of a low-cost screening device for automated physiological and pharmacological profiling of ion channels in high 
throughput mode. 
 
robot. Subsequently, cells were perfused with 100 μl NaCl agonist 
solution containing either increasing concentrations (0.1–100000 nM, 
Fig. 4c) or a single concentration of capsaicin (CAPS, 1 µm, Fig. 4d), 
supplemented with increasing concentrations (0.01–10000 nM) of the 
competitive antagonist capsazepine (CPZ). Fluorescence change was 
calculated as described in the methods section. Sample images of 
HEK293 cells transfected with TRPV1 and loaded with the calcium 
probe Fluo-4 AM are shown in Fig. 4c and d. Average (mean ± SD) 
agonist and antagonist dose–responses are shown in Fig. 4c (n =4) and 
Fig. 4d. (n =3). Calculated half-maximal activation or inhibition 
concentration (EC50, IC50) for capsaicin (29.7 ± 33.7 nM) and capsa- 
zepine (29.3 ± 35.0 nM) basically correspond to data reported in the 
literature (Bevan et al., 1992) and further validate applicability of the 
positioning system for automated functional imaging, i.e. for evaluating 
the physiological and pharmacological characteristics of ion channels 
in high throughput mode. 
Detailed instructions to re-building the device can be found in the 





To overcome the limitations of commercially available positioning 
technology suitable for automated high-content microscopy, we have 
developed a system that is advantageous for several reasons. First, with 
a footprint of 33×20 cm and a mass of 1.1 kg, including controller and 
power supply, the device is smaller and lighter compared to conven- 
tional technology (e.g. Nikon TI-SH-U or Prior Scientific H107/ 
HLD117), allowing for mobile application. The device requires a USB 
connection as well as 5 V DC that could either be provided by a 220V- 
powered supply or even a battery further supporting mobile applic- 
ability. No specific cabling or connectors are needed and operation 
using a laptop and any other handheld device is sufficient. Second, with 
EUR 250 costs of material, the system is approx. 40–80 times less 
expensive compared to commercially available devices and is readily 
applicable to a broad range of laboratories in various fields of research 
and educational institutions. Despite its extremely low costs, the 
positioning characteristics in general and the repeatability in particu- 
lar, compares well with commercially available systems (3.9–5.4 µm vs. 
1 µm for Prior Scientific H107), that could be further improved by 
using e.g. stable closed-loop positioning feedback control systems, 
spindles of smaller pitch as well as by operating the stepper motors in 
half or micro-stepping mode, resulting in finer resolution and higher 
repeatability. Third, the device was prototyped based on a ‘Makers’ 
approach and can easily and quickly be re-built in so called ‘Fab labs’ 
(fabrication laboratories) based on the information provided in the 
paper including supplementary files. Fab labs are small-scale work- 
shops, virtually accessible to anyone and available in many cities and 
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countries (for a list see e.g. https://www.fablabs.io/labs), which are 
increasingly being adopted by schools and universities as platforms for 
project-based, hands-on STEM (science, technology, engineering and 
mathematics) education. Furthermore, as STL and STEP files are 
provided for all 3D printable components it is possible to simply and 
quickly modify individual parts and even the complete stage to meet 
specific requirements. In contrast, hardware modification and 
customization of conventional positioning stages is typically not 
permissible and will result in the loss of warranty and exclusion of 
liability. Additionally, in case of defective hardware, even within the 
warranty period, it typically takes several weeks and even up to months 
until the issue is identified and fixed. Beyond the warranty period, 
replacement of defective parts presumably takes even longer and might 
also generate disproportionately high costs. All 3D printed parts and off-
the-shelf components of the presented device can easily be replaced 
within the same day. For modification of the provided 3D design files, 
there is a variety of free 3D design software available on the internet 
including, e.g. SketchUp Make or FreeCAD. Although building the 
positioning stage based on 3D printed parts is probably the quickest 
and most inexpensive way, the device could also be constructed from 
more durable machined components using different and more robust 
material including injection molding. Fourth, the positioning stage 
presented in this paper is completely open source as we also provide 
any software required to operating the device including Arduino- and 
LabVIEW-based software code. Both programming environments are 
comprehensively documented and support is provided in user forums, 
via tutorials and with a large spectrum of examples allowing the user to 
quickly interface the stage with third-party soft- and hardware without 
being a specialist. For example, most commercial stages are optionally 
equipped with a joystick or related hardware for manual control that – 
with a few thousand euros cost – is typically prohibitively expensive for 
many labs. The presented positioning system could be easily extended 
for manual control using e.g. a few buttons on the computer keyboard 
or a simple joystick for less than a euro as typically implemented in 
conventional gaming controllers. Finally, the device in its current 
configuration is straightforward, easy to use and does not require 
highly skilled staff for application and maintenance as well as expensive 
service contracts thus, further highlighting the applicability in a large 
spectrum of scientific or educational fields. 
Despite the above mentioned advantages over conventional posi- 
tioning stages, the inexpensive open source microscope stage has also 
potential for improvement. For example, all plastic parts were printed 
with a relatively low infill value of 30%, leading to light weight but also 
fragile components. Although in our laboratory the stage has been 
intensively used on a daily basis and for months without functional 
impairment, increasing the fill value may result in increased robustness 
and reliability in long-term applications. In high-throughput screening 
experiments, hardware speed is one of the most important throughput- 
limiting factors. Commercially available positioning devices specify the 
maximal scanning speed with values from 40 (e.g. Prior Scientific 
H107) to 300 mm/s (e.g. Prior Scientific HLD117). Due to LabVIEW- 
related speed limitations for communication with the Arduino board via 
the serial port, the maximum scanning speed of the low-cost device is 
currently limited to 5 mm/s, reducing the achievable experimental 
throughput compared to commercially available high-end motorized 
microscope stages. Some manufacturers indicate the flatness of the 
complete stage (e.g. 5 µm for Prior Scientific H107) as it influences the 
maximally achievable experimental throughput via a given minimal 
range required for autofocussing. The flatness of the low cost device 
was not determined but is presumably in the range of hundreds of 
micro meters. 
Although the system is currently set up for application with 
multititer plates it could easily be extended for use with standard cell 
or tissue culture plastic or glass ware without the need for the device to 
be re-designed. We have created a range of adapters allowing the 
positioning system to be used with standard 26×76 mm glass slides, 40 
and 60 mm dishes as well as T25 and T75 tissue culture flasks. 
Associated 3D design files in STL and STEP format can be found in 
the supplements subfolder named Misc. 
While controlling of the presented device is orchestrated by an 
Arduino microcontroller board and its IDE as well as – optionally - 
LabVIEW, system control could also be realized by other microcon- 
troller prototyping boards such as Raspberry Pi or BeagleBone and 
associated programming languages and operating systems. 
Imaging data generated with our device compares well with data 
obtained using a commercially available microplate reader, demon- 
strating its suitability to high-content microscopy in high-throughput 
screening format and validating its applicability to automated func- 
tional Cl−- and Ca2+-imaging with recombinant HEK293 cells as a model 
system. 
Although this work focusses on automated high-content imaging in 
high-throughput mode, the presented technology could also be ex- 
tended by implementation of further instrumentation including in- 
cubator infrastructure, capable of maintaining optimal conditions 
necessary for culturing organisms such as temperature and carbon 
dioxide or oxygen concentration as well as humidity of the atmosphere 
or other biosensor technology to suit the requirements for a vast variety 
of fields of research including life and even material sciences. 
In summary, the 3D printed motorized positioning stage presented 
in this article improves the classical technologies in terms of port- 
ability, customizability, user-friendliness and cost and provides an 
example of open source low-cost technology that is compatible with fast 
and resource-efficient prototype optimization. Altogether, this work 
contributes to furthering the applicability and availability of commer- 
cially viable automated high-content imaging devices for use in 
biomedical research and education. 
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Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy with about 
30% of patients developing pharmacoresistance. These patients continue to suffer from 
seizures despite polytherapy with antiepileptic drugs (AEDs) and have an increased 
risk for premature death, thus requiring further efforts for the development of new 
antiepileptic therapies. The molecule dimethylethanolamine (DMEA) has been tested as 
a potential treatment in various neurological diseases, albeit the functional mechanism of 
action was never fully understood. In this study, we investigated the effects of DMEA on 
neuronal activity in single-cell recordings of primary neuronal cultures. DMEA decreased 
the frequency of spontaneous synaptic events in a concentration-dependent manner 
with no apparent effect on resting membrane potential (RMP) or action potential (AP) 
threshold. We further tested whether DMEA can exert antiepileptic effects in human brain 
tissue ex vivo. We analyzed the effect of DMEA on epileptiform activity in the CA1 region 
of the resected hippocampus of TLE patients in vitro by recording extracellular field 
potentials in the pyramidal cell layer. Epileptiform burst activity in resected hippocampal 
tissue from TLE patients remained stable over several hours and was pharmacologically 
suppressed by lacosamide, demonstrating the applicability of our platform to test 
antiepileptic efficacy. Similar to lacosamide, DMEA also suppressed epileptiform activity 
in the majority of samples, albeit with variable interindividual effects. In conclusion, DMEA 
might present a new approach for treatment in pharmacoresistant TLE and further 
studies will be required to identify its exact mechanism of action and the involved 
molecular targets. 




Epilepsy is a major neurological disorder affecting up to 65  million people  worldwide  (Hirtz 
et al.,2007;Ngugi et al.,2010). The need for adequate treatment is not only given by seizures   
itself along with associated risks of  injury  and  premature  death  but  also  by  comorbidities  
and social stigmatization. Specifically in focal epilepsy, 30%–40% of patients do not respond to 
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currently available antiepileptic drugs (AEDs), resulting in 
pharmacoresistance with ongoing seizures despite treatments 
with multiple AEDs at high dosages (Stephen et al.,2001). 
Alternative therapies such as ketogenic diet or brain  stimulation 
have been suggested to reduce seizure burden in 
pharmacoresistant patients (Giordano et al.,2014;Kowski et al., 
2015;Dibué-Adjei et al.,2019). However, ketogenic diet has been 
shown to be effective in children and with modification in adults 
but is still rarely considered as treatment in adults (Hallböök    et 
al.,2015;Falco-Walter et al.,2019). Ongoing investigations show 
promising seizure reduction in pharmacoresistant patients by 
deep brain stimulation  (Zangiabadi et al.,2019). However, 
this approach requires optimal selection of targeted brain regions 
and prospective trials are lacking. Finally, surgical removal of 
the epileptic focus remains often the  only  treatment  option  
for pharmacoresistant patients (Wiebe et al.,2001;Engel et al., 
2007). Yet, only in a minority of patients, epilepsy is amenable to 
surgery, and only 60%–70% of resected patients have a positive 
outcome with substantial reduction of the seizure burden 
(International League Against Epilepsy Outcome Scale 1–2; 
Mohan et al.,2018). Thus, identification of new antiepileptic 
treatment options in focal pharmacoresistant epilepsy is of 
paramount importance. 
Dimethylethanolamine (DMEA) has previously been 
investigated as a stimulant and treatment for several neurological 
diseases, including tardive dyskinesia (TD), Alzheimer’s disease 
(AD) and senile dementia (Ferris et al.,1977; Penovich et al., 
1978;  de Montigny et al., 1979;  Fisman et al., 1981; George 
et al.,1981). First, application of DMEA to human healthy 
volunteers dates back to the 1960s when DMEA was reported  
to exert stimulating effects comparable to amphetamine 
(Murphree et al.,1960; Pfeiffer et al.,1963). Murphree et al. 
(1960) described improved concentration, increased  muscle tone 
and changed sleeping habits in healthy males (21–26 years) 
with an  intake  of 10–20 mg  DMEA (or Deanol) daily for 
2-3 weeks compared to a placebo group. In later studies, DMEA 
was hypothesized as an acetylcholine (ACh) precursor and 
therefore tested in diseases that are considered to be linked to the 
cholinergic system. However, results of several studies were 
inconclusive and a systematic review could not confirm the 
positive effects of DMEA or other cholinergic compounds in 
patients with TD (Tammenmaa et al.,2004). In addition, in vivo 
experiments showed that DMEA is not methylated to choline and 
does not alter brain ACh levels (Millington et al.,1978;  
Jope and Jenden,1979). 
Interestingly, in both acute and chronic seizure models in rats, 
a conjugate of DMEA and valproate (DEVA) was shown to be 
more potent than valproate alone, potentially by facilitation of 
valproate transport via the blood brain barrier (Shekh-Ahmad 
et al., 2012). In this study, however, the effects of DMEA 
alone were not tested. To our knowledge, effects of DMEA 
on pathological neuronal network activity have never been 
investigated before. 
In principle, resected human tissue of temporal lobe epilepsy 
(TLE) patients carries the potential to bridge the translational 
gap between preclinical and clinical drug development. Animal 
models have been instrumental in the discovery and preclinical 
development of novel AEDs (Löscher,2011). However, animal 
models cannot represent all aspects of complex neurological 
disorders and sometimes produce misleading results as 
exemplified by the neuropeptide galanin. Galanin showed 
robust antiepileptic effects in a mouse model of epilepsy, 
however, the effect could not be reproduced in resected human 
tissue (Ledri et al.,2015). 
Here, we decided to investigate the effects of DMEA on 
epileptiform activity directly in ex vivo human tissue resected 
from epilepsy patients. 
MATERIALS AND METHODS 
Primary Rat Hippocampal Neuronal Cell 
Culture 
Hippocampal cultures from E18 Wistar rat embryos were 
prepared as previously described (Winkelmann et al.,2014) 
according to the approval by the Animal Care Committee of 
the Technical University Braunschweig (Zentrale Einrichtung 
für Tierhaltung der TU Braunschweig, §4 10.15.R  TSB  TU 
BS) and maintained in Neurobasal medium supplemented with 
B27 and 1% FCS (Brewer et al.,1993). Hippocampal neurons 
were subjected to whole cell patch clamp analysis at DIV13–16 
to ensure that the cultures were mature enough to display 
synaptic activity. 
Electrophysiological Recordings of 
Cultured Hippocampal Neurons 
An EPC-7 amplifier (List-Medical, Darmstadt, Germany), ITC-
18 interface and Patchmaster software (both HEKA, Lamprecht, 
Germany) were used for patch clamp recordings and data 
acquisition. Patch pipettes made from borosilicate  glass (Science 
Products, Hofheim, Germany), had resistances of 4–7 MK when 
filled with the intracellular solution containing (in mM): KCl 
(130), NaCl (5), CaCl2 (0.5), MgCl2 (1), EGTA 
(5) and HEPES (30), pH 7.2 (KOH). Neurons were continuously 
perfused with carbogenated artificial cerebrospinal fluid (aCSF) 
containing (in mM): NaCl (125), KCl (2), MgCl2 (1), CaCl2  (2), 
NaHCO3 (25), NaH2PO4 (1.25) and glucose (10), pH 7.4. 
Extracellular solution was supplied by gravity using a perfusion 
pencil (Automate Scientific Inc., Berkeley, CA, USA) for fast 
solution exchange. The extracellular solution was supplemented 
with 0.5, 2, 5 or 10 mM DMEA. Series resistances (Rs) were 
monitored by 5 mV voltage pulses (50 ms) applied every 5 s and 
varied between 10 MK and 30 MK. Data were acquired with a 
sampling rate of 20 kHz and filtered at 2.8 kHz. All experiments 
were carried out at room temperature  ( 24◦C). 
The effect of DMEA on synaptic activity and excitability was 
tested in current-clamp mode with stepwise increase of DMEA 
concentration. DMEA was applied for 60 s, following 3–5 min 
wash-out with aCSF before applying the next drug concentration. 
No synaptic or intrinsic blockers were added. A steady current 
injected into the cell was used to hold the membrane potential 
around 50 mV never exceeded 150 pA. Action potential (AP) 
threshold was investigated by short  current  injections  using  
10 pA steps with or without the application of DMEA. AP 
threshold was determined as the mean between the  minimum 
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membrane potential necessary for AP generation and membrane 
potential of the previous step current. 
Human Tissue Transport and Preparation 
Human hippocampal tissue from epilepsy surgery  was  collected 
from 12 TLE patients  (10  males,  two  females),  who all gave 
written consent prior to the procedure. Experiments were 
approved by the Ethics Committee of Charité-
Universitätsmedizin Berlin on the 1st of November 2014 
(EA2/111/14) and performed in agreement with the Declaration 
of Helsinki. 
Hippocampal tissue was transferred to carbonated (95% O2, 
5% CO2), ice-cold transport solution immediately after resection. 
Tissue  was  transported  to  the  lab  in  <60  min  and  cut  to 
400  µm  slices  using  a  vibratome  (Leica  VT1200S, Wetzlar, 
Germany). N-methyl d-glucamine (NMDG)-aCSF was used for 
brain tissue transport and slice preparation from patients 1–7, 
while choline-aCSF was used to handle tissue of patient 8–12 in 
order to optimize transport. NMDG-aCSF contained (in mM): 
NMDG (93), KCl (2.5), NaH2PO4 (1.2), NaHCO3 (30), MgSO4 
(10), CaCl2 (0.5), HEPES (20), glucose (25), Na-L-ascorbate (5), 
thiourea (2), Na-pyruvate (3;Ting et al.,2014). Choline-aCSF 
contained (in mM): Choline chloride (110), KCl (2.5), NaH2PO4 
(1.25), NaHCO3 (26), MgCl2 (7), CaCl2 (0.5), glucose (10), Na- 
L-ascorbate (11.6), Na-pyruvate (3.1;Testa-Silva et al.,2010). 
As  part  of  the  standard  clinical  routine,   every   third slice 
collected during the slicing procedure was fixed in 4% 
paraformaldehyde (PFA, pH 7.4, phosphate-buffered saline) and 
analyzed for pathological alterations. For electrophysiological 
recordings, slices were stored in an interface chamber for a 
recovery period of at least 5 h and continuously perfused with 
carbogenated aCSF containing (in mM): NaCl (129), NaH2PO4 
(1.25), CaCl2 (1.6), KCl (3.0), MgSO4 (1.8), NaHCO3 (21), 
Glucose (10; 1.6 ml/min, 35◦C, pH 7.4). All slices were studied 
between 6 h and 20 h after resection. 
Electrophysiological Recordings of Human 
Tissue 
For electrophysiological recordings, slices were transferred to a 
custom modified version of the membrane chamber (Hill and 
Greenfield,2011) and perfused with aCSF (10 ml/min, 32 ◦C). 
The membrane chamber is a submerged-type recording chamber 
with a high flow rate but stable slice position, guaranteeing 
optimal oxygen supply and fast drug applications. Field potential 
recordings were performed with borosilicate pipettes (1.5 mm 
outer diameter, Science Products, Hofheim, Germany) pulled 
with a vertical puller (1–2 MK, PC-10, Narishige, Tokyo, Japan) 
and filled with NaCl (154 mM). Signals were recorded from CA1 
pyramidal cell layer, sampled at 10 kHz, low-pass filtered at 2 
kHz by a Digidata 1550 interface and processed by PClamp10 
software (Molecular Devices, Sunnyvale, CA, USA). 
Induction of epileptiform activity in rodent brain slices can 
be achieved by a stand-alone manipulation such as inhibition 
of potassium channels by 4-aminopyridine (4-AP; Perreault and 
Avoli, 1991; Avoli et al., 2002; Heuzeroth et al., 2019). On the 
contrary, induction of epileptiform activity in human brain tissue 
ex vivo is less straightforward and subject to controversy. 
In resected human brain tissue only application of 4-AP in 
combination with electrical stimulation or elevated extracellular 
potassium was able to show stable induction of epileptiform 
activity, not application of 10 or 12 mM potassium or 4-AP alone 
(Gabriel et al.,2004;Antonio et al.,2016). Here, we used bath 
application of high potassium (8 mM) and 4-AP (100 µM, Sigma, 
Munich, Germany) for the  induction  of  epileptiform activity in 
human brain tissue. Increase of osmolarity by 8 mM KCl 
was balanced by lowering NaCl concentration from 129 mM to 
124 mM. 
Baseline epileptiform activity was recorded for ≥20 min. 
DMEA (10 mM, Sigma, Munich, Germany) or lacosamide 
(LAC, 100 µM, Biozol, Eching, Germany) were then applied 
for ≥20 min, followed by ≥20 min of wash-out. In initial 
experiments we tested 5 mM and 10 mM of DMEA in the same 
slice, starting with 5 mM DMEA (20 min), followed by 10 mM 
DMEA and wash-out as described above. 
Addition of DMEA increases osmolarity of aCSF possibly 
affecting neuronal activity. Therefore, we performed control 
experiments with increasing the osmolarity of  aCSF  up  to 310 
mOsm by addition of 10 mM sucrose (patients 10, 11, and 12). 
This approach has been used to test hyperosmolar solutions 
before (Rosenmund and Stevens,1996). Here, the recording 
sequence stated above was modified and consisted of the 
following steps: (1) baseline with stable epileptiform activity 
(≥10 min); (2) 10 mM sucrose (≥20 min); and (3) wash-out 
sucrose (≥10 min), 10 mM DMEA (≥20 min), wash-out DMEA 
(≥20 min). 
Data Analysis and Statistics 
Electrophysiological data recorded in single cells from primary 
neuronal cell cultures was quantified and measured using an 
IGOR Pro (Version 6.3.7.2, Wavemetrics Inc., Oregon, USA) 
procedure written by Dr. Marcus Semtner (MDC Berlin) and the 
extension PatchersPowerTools (written by Dr. Francisco Mendez 
and Frank Würriehausen). 
Recordings in human hippocampal tissue were band pass 
filtered (1–1,000 Hz) and the 300 s long episodes (last 5 min   of 
each application phase) were analyzed with Clampfit 10.7 
(Molecular Devices, Sunnyvale, CA, USA) threshold analysis. All 
events visually identified as burst activity (defined by biphasic, 
positive and negative deflection and a duration ≥100 ms) were 
manually indicated for further analysis of event frequency (inter- 
event-interval, IEI), amplitude and total number of events during 
the analyzed time frame. Interictal spikes (defined by exclusive 
negative deflections and a duration <10 ms) were not analyzed. 
According to literature, interictal spikes, although pathologically 
relevant, are not significantly affected by AEDs (Spencer et al., 
2008;D’Antuono et al.,2010). 
All data were analyzed with GraphPad Prism 5 (GraphPad 
Software Inc., San Diego, CA, USA). Prior to analysis, data were 
subjected to D’Agostino and Pearson omnibus normality test and 
analyzed accordingly. In cases where sample size of tested 
groups was too small for evaluation of data distribution, data 
were analyzed using non-parametric tests. 
Statistical analysis of normal distributed data was performed 
using repeated measurement analysis of  variance  (ANOVA) 
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and post hoc Tukey’s comparison of all groups. Non-normal 
distributed data or data with small sample size was analyzed 
either using Friedman test and post hoc Dunnett’s multiple 
comparison of individual groups or  Wilcoxon  signed-rank  
test. For all analysis, a p-value < 0.05 was considered 
statistically significant. 
Data analyzed by parametric tests were presented as scatter 
plots with mean ± standard deviation (SD) while data analyzed 
by non-parametric tests were presented as scatterplots with 
median and interquartile range. Due to IEI variance during  
drug application (DMEA or  LAC),  frequency  of  events  for 
all patients was summarized as number of events. IEI for 
individual recordings is presented as boxplots with median and 
Tukey whiskers (1.5 the interquartile distance) to show data 
distribution and inter-individual differences. 
Human   datasets   analyzed   in   this   study   can   be   
found in figshare repository (https://doi.org/10.6084/m9. 
figshare.8148572). 
RESULTS 
To investigate whether DMEA  affects  neuronal  activity  and to 
obtain information about potential molecular targets, we 
performed electrophysiological recordings in primary neuronal 
cultures. DMEA dose-dependently reduced spontaneous 
synaptic events and associated APs with an estimated EC50 of 
~ 0.5–1.0 mM. A full  block  of  activity  was  observed  in 
all recorded cells when using 5 mM or 10 mM DMEA 
(Figures 1A,B,D,E). Neither resting membrane potential 
(RMP) nor AP threshold changed upon DMEA application 
(Figures 1C,F, Supplementary Figures S1A,B), suggesting 
that  intrinsic  properties  do  not  represent  the main target of 
DMEA action. 
We also investigated the effects of DMEA on epileptiform 
activity in hippocampal tissue resected from 12 patients 
undergoing epilepsy surgery. Histopathology  of  resected  tissue 
revealed distinct pathologies: malformations of cortical 
development (MCD) were diagnosed in two patients [mild MCD 
changes in one and clear focal cortical dysplasia (FCD) in the 
other patient], unspecific astrogliosis in three patients and clear 
pathological changes indicating  hippocampal  sclerosis  (HS)  
in seven patients (Supplementary Table S1). The changes in 
pyramidal layers of CA1, CA3 and CA4 included <10% neuronal 
cell loss in three patients (Wyler grade 1), up to 50% cell loss in 
three patients (Wyler grade 2) and more than 50% cell loss in 
one patient (Wyler grade 3). 
From these 12 resected samples, a total of 30 hippocampal 
slices was used for electrophysiological recordings. After slice 
recovery, we tested our experimental approach by assessing 
whether: (1) epileptiform activity in human slices can be induced 
by elevated potassium and 4-AP; (2) whether this activity is stable 
for prolonged periods of time; and (3) sensitive to conventional 
AEDs. In 27 slices from 12 patients, both interictal spikes and 
ictal burst activity (Figures 2A,B) could be induced within a few 
minutes (Figures 2C,F). In three slices from three patients, burst 
events did not occur within 20 min, therefore these slices were 
excluded from the analysis. 
In control recordings without drug application, the 
pathologically  relevant  burst  activity  was  stable  for   at 
least 60 min (tested in three slices from three patients), 
suggesting good viability of human slices in our experimental 
setting. In more detail, both  frequency  and  amplitude of 
burst activity did not change in most cases during  the recording 
as indicated by stable IEI, amplitude and number of burst events 
(Figures 2D,E). 
To test whether burst activity was sensitive to conventional 
AEDs, we investigated the effect of the sodium channel blocker 
LAC. During application of LAC, IEI increased in all recorded 
slices, which was reversible in three out of four patients   
(Figure 2G). Number of events of all recordings decreased 
during LAC application when compared to baseline activity, 
while amplitude of burst activity did not change (Figure 2H). 
In conclusion, we were able to induce stable epileptiform 
activity that can be inhibited by clinically approved AEDs. 
Next, we investigated the effects of DMEA in 14 hippocampal 
slices from 10 TLE patients. In initial experiments, we tested 
the effects of 5 mM and 10 mM DMEA within one experiment 
(Supplementary Figure S2). As the inhibitory effect  was  
more robust when using 10 mM DMEA (Supplementary 
Figure S2B, p < 0.05, n = 6; tested in patients 2–7), we 
decided to perform subsequent experiments with this effective 
concentration. In contrast to LAC, DMEA effects varied 
considerably between samples ranging from no effect (patient 8, 
Figure  3A)  or  only  a  moderate  effect  observed  in  slices  
of patient 7 (Figure 3B) to a full block of burst  activity  
(Figure 3C) in four slices from patients 9, 10 and 11. Irrespective 
of the effect variability, DMEA displayed antiepileptic effects in 
10 out of 11 patients (Figure 4A), as indicated by the increase 
of IEI and a significant decrease of number of events during 
application of DMEA (Figure 4B, p < 0.01, n = 10).   In eight 
patients, these effects were clearly reversible upon wash-out of 
DMEA. Amplitude of epileptiform bursts was not affected 
(Figure 4C). 
Addition of DMEA  at  10  mM  increases  osmolarity  of  the 
extracellular environment (here, aCSF) which could  possibly 
decrease epileptiform activity simply by osmotic effects 
(Traynelis and Dingledine,1989;Dudek et al.,1990). 
To test whether DMEA effects are mediated by mechanisms 
beyond pure change in osmolarity, we investigated  how 
sucrose and DMEA affect epileptiform activity in the  same 
slice when applied sequentially. In six slices of three patients 
increase of osmolarity by sucrose (310 ± 5 mOsm) to match 
osmolarity of solutions  containing  10  mM  DMEA  resulted  
in a weak increase of IEI and a weak decrease of number of 
events (Supplementary Figure S3). This decrease matched the 
observed decrease without intervention  over  time  as  shown  
in Figure 2E and was likely due to a slow decay in activity in 
the course of in vitro experiments. The mild effect of sucrose 
application stood in contrast to a full block of activity during 
subsequent application of  DMEA  in patients 10 and 11 and 
a strong decrease of activity in patient 12 (Supplementary 
Figures S3A,B). 
In summary, in human brain slices DMEA exerted 
antiepileptic effects presented as an overall decrease in frequency 
Frontiers in Molecular Neuroscience|www.frontiersin.org 5 September 2019 | Volume 12 | Article 209  




of burst events, which were not due to osmotic changes. A 
summary of all results is presented in Supplementary Table S2. 
 
DISCUSSION 
In the present study, we investigated the effect of DMEA on 
spontaneous activity in neuronal cultures and on epileptiform 
activity in  human hippocampal  tissue ex  vivo. We were able    
to show a decrease of spontaneous activity in rodent neuronal 
cultures. In the majority of investigated human slices, DMEA 
displayed strong antiepileptic effects including full block of burst 
activity in slices of three patients. The effect of DMEA in human 
tissue varied considerably, implying interindividual differences 
in expression patterns of molecular DMEA targets. 
The mechanism of DMEA action is not known. Our 
preliminary experiments in neuronal cultures showing  
dose-dependent inhibition of spontaneous neuronal activity 
without altering RMP or AP threshold suggest that DMEA likely 
affects synaptic but not intrinsic excitability. In previous clinical 
studies, DMEA was tested as a potential ACh precursor but did 
not improve disease symptoms in TD or AD. DMEA increased 
choline concentrations in plasma  and brain  though  this  did not 
affect brain ACh concentrations, questioning a beneficial effect 
of DMEA in diseases involving the cholinergic system 
(Millington et al., 1978; Jope and Jenden, 1979). Nevertheless, 
due to structural similarities of DMEA, ACh and choline, 
muscarinic ACh  receptors (mAChRs)  present possible targets 
of DMEA action. ACh and choline are both ligands of M2 and 
M3 mAChRs (Shi et al., 2004; Moreno-Galindo et al., 2016), 
which upon activation increase the open probability of G-protein 
coupled inwardly rectifying potassium (GIRK) channels, 
specifically GIRK1 and GIRK4 (Nemec et al.,1999). GIRK1 and 
with increasing DMEA concentration to reach a full block with 5 mM DMEA. (A,D) Exemplary recordings in neurons with application of 0.0, 0.5, 2.0 and 5.0 mM 
DMEA (A) or 10 mM DMEA (D); note that due to experimental setup we could not perform repeated measurement in one cell including all concentrations and 
present the results here separately; Dashed lines below recordings indicate resting membrane potential (RMP, in mV) of cells. (B,E) DMEA significantly decreases 
event frequency in a concentration-dependent manner. (C,F) Application of DMEA does not affect RMP. All data are shown as scatter plots with median and 
interquartile range. Asterisks mark significant differences as assessed by Friedman test and post hoc by Dunnett’s multiple comparison of groups (B,C) or by 
Wilcoxon signed-rank test (E,F; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001). Scale bar: 10 mV, 0.5 s. 
excitatory synaptic events with associated action potentials (APs) at a frequency of ∼1 Hz. Both AP, as well as large amplitude synaptic event frequency, decreased 
FIGURE 1 | Dimethylethanolamine (DMEA) decreases spontaneous neuronal activity in neuronal cultures in a concentration-dependent manner. Activity of cultured 
hippocampal neurons (DIV 13–16) was investigated in current-clamp mode in the absence or presence of DMEA. During baseline conditions, all neurons displayed 
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FIGURE 2 | Epileptic burst activity in human slices is stable over long time periods and decreases during application of lacosamide. Application of 8 mM K+ and 
100 µM 4-aminopyridine (4-AP) induces two patterns of network activity recorded by field potential electrodes in the CA1 area of human hippocampal slices: 
interictal spikes (A) and burst activity (B). (C–E) Burst activity is induced a few minutes after application and stable for at least 60 min. (F–H) Induced burst activity 
decreases during application of lacosamide (LAC). (C,F) Exemplary recording with excerpts of regions used for analysis. (D,G) Inter-event intervals (IEI) of individual 
recordings shown as box plots with mean and 1.5× interquartile distance. Each dot represents data point outside the 1.5× interquartile distance. Total number of IEI 
during analyzed time frame are indicated in brackets. (E,H) Summarized results for all patients [number of events and amplitude as mean ± standard deviation (SD)]; 
each dot indicates one patient. Asterisks mark significant differences as assessed by Friedman test and post hoc with Dunnett’s multiple comparison of groups 
(p < 0.05). T1, T2, T3 in (D,E) are periods analyzed for each patient, comparable to analyzed times in (G,H) and Figure 3. Scale bars: 0.2 mV, 500 ms (A,B), 5 min 
(full recording, C), 2 min (full recording, F), 5 s (excerpts, C,F). 
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GIRK4 are expressed in the hippocampus (Miyashita and 
Kubo,1997;Murer et al.,1997;Cea-del Rio et al.,2010) and 
pharmacological activation of GIRK results in antiepileptic 
effects in vitro and in vivo (Kaufmann et al.,2013). Thus, M2 or 
M3 mAChRs and GIRK channels present a possible mechanism 
for DMEA action. 
Another possible candidate are glycine receptors (GlyR). In a 
separate project, our group analyzed the  effects  of  DMEA on 
GlyR, which has been described as subject to  increased RNA 
editing in TLE (Krestel et al.,2013;Winkelmann et al., 
2014;Meier et al.,2016;Srivastava et al.,2017). Presynaptic 
RNA-edited GlyR facilitates neurotransmitter release resulting  
in  increased  neuronal  gain  and,  depending  on  the neuronal 
subtype,  network  hyper-  or   hypoexcitability  (Winkelmann et 
al.,2014;Caliskan et al.,2016). In an initial screen 
for antagonists against RNA-edited GlyR (data not shown), 
DMEA was considered as a candidate giving an additional 
incentive to test this substance in human brain slices. However, 
confirmatory experiments were not able to reproduce DMEA 
specificity against RNA-edited GlyR. Overall, the molecular 
targets of DMEA and its mechanism of action in brain tissue 
remain indeterminate. 
The main goal of  our  study  was  to  demonstrate  a  
possibly clinically relevant effect  of  DMEA.  DMEA  has  
been tested in patients and healthy volunteers since 1960s 




























Frontiers in Molecular Neuroscience|www.frontiersin.org 8 September 2019 | Volume 12 | Article 209  







Murphree  et  al. (1960)  reported  no  change  in  heart   rate, 
body weight, muscle power, hand steadiness or vital capacity 
with  an intake of 10–20  mg  DMEA  (or  Deanol)   daily  for   
2–3 weeks. In two double-blinded, placebo-controlled studies  of 
TD, DMEA led to side effects such as lethargy, drowsiness and 
a  mild  but  significant  increase  in  the  schizophrenia  score  
(de  Montigny  et  al.,  1979;  George  et  al.,  1981),  although 
a  systematic  review   was not able  to  confirm  an  increased  
risk for psychosis (Tammenmaa et al.,2004).Fisman et al. 
(1981)detected severe neurological and cardiovascular effects 
(apathy, motor retardation, increased confusion associated with 
rise in  systolic  and  diastolic blood pressure) in two patients  
with AD when treated with 1,800 mg DMEA daily. In these 
studies,  as  compared   to  Murphree  et al. (1960), DMEA  was 
administered in a 100-fold higher daily dosage (10–20 mg vs. 
1,000–2,000 mg).  A  dose of 2,000   mg DMEA corresponds to 
a molar amount of 22 mM and  a final in vivo concentration  
of 0.44 mM assuming a distribution across all compartments 
and a body water content of approximately 50 l for an adult 
male. This concentration is lower by a factor of 20 when 
compared to 10 mM tested to be effective in human  brain  
tissue ex vivo in our study, and this difference is rather 
underestimated when taking into account oral bioavailability.  
Of note, in neuronal cultures, the effective concentration to 
inhibit neuronal activity was lower by a factor of 10, implying 
that differences in microenvironment, neuronal connectivity  
and drug diffusion in different preparations and species might 
influence the effective concentration. 
FIGURE 4 | DMEA reduces epileptiform activity in human hippocampal slices. Summary of DMEA effects on burst activity recorded in CA1 pyramidal cell layer of 
resected human hippocampus. (A) Box plots of IEIs with mean and 1.5× interquartile distance before, during and after DMEA application for each patient are shown 
as scatter plots with mean ± SD, asterisks mark significant differences as assessed by repeated measurement analysis of variance (ANOVA) and post hoc with 
Tukey’s comparison (∗∗ p < 0.01, n = 10). 
for all recorded slices (n = 10 patients). Dots represent data points outside the 1.5× interquartile distance. Total number of IEI during analyzed time frame are 
indicated in brackets. (B) Summary of DMEA effects on number and (C) amplitude of burst events for all patients; each dot indicates one patient. Data is presented 
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Addition of DMEA to our experimental solution increased the 
osmolarity by 10 mOsm. In previous studies, application 
of hyperosmolar solutions decreased neuronal excitability and 
epileptiform activity, but in most cases, an increase of 30 mOsm 
and more was necessary to induce  these  effects  (Traynelis  and 
Dingledine, 1989; Dudek et al., 1990; Rosen and Andrew, 1990). 
According toRosen and Andrew(1990), an increase of 
extracellular osmolarity by 10 mOsm might result in a 10% 
decrease of EPSC amplitude in CA1 pyramidal neurons, but the 
effects of such EPSC alteration on network activity have not been 
investigated. Here, increase of aCSF osmolarity by application of 
10 mM sucrose did not alter epileptiform activity, indicating that 
the antiepileptic effects of DMEA are not primarily mediated by 
changes in osmolarity. 
Although our study clearly demonstrated an antiepileptic 
effect of DMEA, the large concentration difference between our 
work and previous clinical studies and the variability of 
underlying pathologies represent substantial limitations. The 
results suggest heterogeneous expression of DMEA targets, 
however, also differences in neuronal survival and the degree  of  
HS  could  possibly  contribute.  An  additional  limitation   is 
given by different transport solutions used in our study, namely 
either NMDG or choline aCSF  (Testa-Silva et al., 2010; Eyal et 
al.,  2018; Ting et al.,  2018).  Although we were unable to detect  
differences  in  tissue  quality  as  seen  by stable induction and  
properties  of  epileptiform  activity,  we cannot exclude 
differences in neuronal survival between these solutions. 
The predictive value of brain activity for drug development 
in  an  ex  vivo  setting  is  still  unclear.  In  our   approach 
using a modified submerged chamber, we mostly observed 
burst  activity  (spike  and  burst   activity)   described  before as  
interictal-like  (Remy  et  al.,  2003;  Gabriel et al.,  2004; 
Sandow et al., 2015;  Reyes-Garcia et  al., 2018)  and  standing 
in contrast to ictal discharges lasting >10 s. Brückner and 
Heinemann (2000)  suggested  that  AEDs  applied   in brain 
slices (of non-epileptic animals) rather inhibit ictal but not 
interictal activity. Other animal studies in vitro, however, 
demonstrated a robust decrease in interictal activity in the 
hippocampus upon AED application (Fueta and Avoli, 1992; 
Holtkamp et al., 2017; Taing et al., 2017), which was 
comparable  to our results with LAC and  DMEA.  We show 
that burst activity was sensitive to the approved antiepileptic 
LAC, indicating that our experimental setting is capable of 
validating  and  possibly predicting antiepileptic efficacy for  
drug development. 
Taken together, our work identified the antiepileptic effect  of 
DMEA in human hippocampal tissue from TLE patients. 
Interindividual effect variability, differences in the effective 
concentration range and previously reported side effects call for 
future, more detailed investigation of cell-type specific effects and 
molecular targets of DMEA. 
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FIGURE S1 | DMEA does not change action potential threshold. Application of 
10 mM DMEA does not change threshold for AP generation. (A) Exemplary 
recordings of patch-clamp recordings in current-clamp mode with step current 
without AP (first for each) and with AP generation (second); dashed lines below 
recordings show −60 mV value to indicate RMP of cells. (B) Quantified effect of 
DMEA on AP threshold in neurons. Data are shown as median with interquartile 
range and was subjected to Wilcoxon signed-rank test; n = 6. 
 
FIGURE S2 | Dose-dependent effects of DMEA on epileptiform activity in human 
hippocampal slices. (A) Box plots of inter-event intervals (IEI) during baseline, 
5 mM DMEA, 10 mM DMEA and wash-out for each patient given for all recorded 
slices (n = 6 patients). In all experiments, both concentrations were applied in the 
same brain slice. Box plots are shown with mean and Tukey whiskers (1.5× 
interquartile distance). Each dot represents a data point outside the 1.5× 
interquartile distance. Total number of IEI during analyzed time frame are indicated 
in brackets. (B) Summary of DMEA effects on the number and amplitude of burst 
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events for all tested patients; each dot indicates one patient. Data are presented 
as scatter plots with median ± interquartile range. Asterisks mark significant 
differences as assessed by Friedman test and post hoc with Dunnett’s multiple 
comparison of groups (∗ p < 0.05). 
 
FIGURE S3 | Increase of osmolarity by 10 mOsm does not affect epileptiform 
activity. For control purposes, sucrose was used to increase osmolarity and 
applied in the same slice before DMEA application. (A) Full time course and 
detailed excerpts of exemplary recording used for the analysis of potential 
hyperosmotic effects of DMEA on epileptiform activity. Note that sucrose 
application leading to the same osmotic change as DMEA does not significantly 
alter epileptiform activity, while DMEA application in the same slice clearly exerts 
an antiepileptic effect. (B) Inter-event intervals of individual recordings shown as 
box plots with a total number of IEI during analyzed time frames indicated in 
brackets. (C) Summarized number of events and amplitudes for all patients 
presented as scatterplots with median and interquartile range; each dot indicates 
one patient. Scale bars: 0.2 mV, 5 min (full recordings), 5 s (excerpts). 
 
TABLE S1 | Clinical data of patients, who provided tissue for 
electrophysiological assessment of the effects of DMEA on epileptic activity. 
 
TABLE S2 | Summarized results of burst activity in human tissue during 
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